Korean Journal of Sport Science

Search

Close

์ฃผ์š” ๊ทผ์œก๋ณ‘๋ฆฌ ์†Œ๊ฒฌ์„ ๋ฐ”ํƒ•์œผ๋กœ ํ•œ ๊ทผ์œก๋ณ‘์˜ ์ง„๋‹จ

Diagnostic Approaches to Various Muscle Diseases Based on Muscle Pathology

Young-Eun Park, MDa,b, Jin-Hong Shin, MDa,c, Dae-Seong Kim, MDa,c

์ฃผ์š” ๊ทผ์œก๋ณ‘๋ฆฌ ์†Œ๊ฒฌ์„ ๋ฐ”ํƒ•์œผ๋กœ ํ•œ ๊ทผ์œก๋ณ‘์˜ ์ง„๋‹จ

๋ฐ•์˜์€a,b, ์‹ ์ง„ํ™a,c, ๊น€๋Œ€์„ฑa,c
Received May 25, 2021; ย  ย  ย  Revised July 8, 2021; ย  ย  ย  Accepted July 8, 2021;
ABSTRACT
Muscle pathology can give much information to reach the diagnosis of neuromuscular disorders. Major pathological changes occurred in skeletal muscles include muscle fiber atrophy/hypertrophy, necrosis/regeneration, inflammation, myofibrillar disorganization, abnormal inclusions, and disruptions in cellular organelles. Physicians should be able to understand what each of these findings indicates. However, these are not always specific to a certain disease, and instead most of them are commonly found in many of muscle diseases. Thus, muscle pathological findings should be carefully interpreted under the given clinical settings.
์„œ ๋ก 
์„œ ๋ก 
๊ทผ์œก๋ณ‘์€ ๊ทผ์œก์กฐ์ง์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ๋‹ค์–‘ํ•œ ๋ณ€ํ™”๋กœ๋ถ€ํ„ฐ ๊ธฐ์ธํ•œ๋‹ค. ๊ทผ์œก์€ ์ˆ˜์ถ•๊ณผ ์ด์™„์„ ํ†ตํ•ด ๊ทผ๋ ฅ์„ ์ƒ์„ฑํ•˜๋Š” ๊ธฐ๊ด€์ด๋ฏ€๋กœ ๊ทผ์œก์กฐ์ง์˜ ์ด์ƒ์€ ๊ถ๊ทน์ ์œผ๋กœ ๊ทผ๋ ฅ์„ ์•ฝํ™”์‹œํ‚จ๋‹ค. ๋”ฐ๋ผ์„œ ๋ชจ๋“  ๊ทผ์œก๋ณ‘์€ ๊ทผ์‡ ์•ฝ๊ณผ ๊ทผ์œ„์ถ•์ด๋ผ๋Š” ๊ณตํ†ต์ ์ธ ์ฆ์ƒ๊ณผ ์ง•ํ›„๋ฅผ ๋‚˜ํƒ€๋‚ธ๋‹ค. ์ž„์ƒ์ ์œผ๋กœ ๊ทผ์‡ ์•ฝ์ด ๋ฐœ์ƒํ•˜๋Š” ๋ถ€์œ„์™€ ์–‘์ƒ์— ๋”ฐ๋ผ ๊ทผ์œก๋ณ‘์˜ ๊ฐ๋ณ„์ง„๋‹จ์ด ๊ฐ€๋Šฅํ•œ ๊ฒฝ์šฐ๋„ ์žˆ์œผ๋‚˜ ๋งŽ์€ ๊ฒฝ์šฐ์—๋Š” ๊ทผ์œก์˜ ์กฐ์ง ์†Œ๊ฒฌ์„ ๊ด€์ฐฐํ•˜๋Š” ๊ฒƒ์ด ์ง„๋‹จ์„ ์œ„ํ•ด ํ•„์š”ํ•˜๋‹ค. ์ตœ๊ทผ ์œ ์ „์ž๊ฒ€์‚ฌ์˜ ๋ฐœ๋‹ฌ๋กœ ๊ทผ์ƒ๊ฒ€์„ ์ƒ๋žตํ•˜๊ธฐ๋„ ํ•˜์ง€๋งŒ, ์ด๋Š” ๋Œ€๋ถ€๋ถ„ ์ž„์ƒ ์†Œ๊ฒฌ์„ ๋ฐ”ํƒ•์œผ๋กœ ์›์ธ์œ ์ „์ž๋ฅผ ์‰ฝ๊ฒŒ ํ•œ์ •ํ•  ์ˆ˜ ์žˆ๋Š” ๊ฒฝ์šฐ์— ๊ตญํ•œ๋œ๋‹ค. ํ•œํŽธ, ์ˆ˜๋งŽ์€ ํ›„๋ณด์œ ์ „์ž๋ฅผ ํ•œ๊บผ๋ฒˆ์— ๋ถ„์„ํ•  ์ˆ˜ ์žˆ๋Š” ๊ฒ€์‚ฌ ๋ฐฉ๋ฒ•์ธ ์ฐจ์„ธ๋Œ€์—ผ๊ธฐ์„œ์—ด๋ถ„์„์€ ๊ทผ์œก๋ณ‘์˜ ์œ ์ „์ง„๋‹จ์„ ๋งค์šฐ ํ–ฅ์ƒ์‹œ์ผฐ์œผ๋‚˜ ์ด๋ฅผ ํ†ตํ•ด ์–ป์€ ๊ด‘๋ฒ”์œ„ํ•œ ์œ ์ „ ์ •๋ณด๋“ค ์ค‘์—์„œ ์›์ธ์ด ๋˜๋Š” ๋ณ€์ด๋ฅผ ์ •ํ™•ํ•˜๊ฒŒ ์ฐพ์•„๋‚ด๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ž„์ƒ์ •๋ณด์™€ ๋”๋ถˆ์–ด ๊ทผ์œก์˜ ์กฐ์ง ์†Œ๊ฒฌ์ด ์ค‘์š”ํ•œ ๋‹จ์„œ๊ฐ€ ๋  ์ˆ˜ ์žˆ๋‹ค.
๊ทผ์œก๋ณ‘์ด ์˜์‹ฌ๋˜๋Š” ํ™˜์ž์—์„œ ๊ทผ์ƒ๊ฒ€์„ ํ•˜์˜€์„ ๋•Œ ์ฃผ๋กœ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ์†Œ๊ฒฌ์€ ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ, ๊ทผ์„ฌ์œ ์˜ ํฌ๊ธฐ์™€ ๋ชจ์–‘์˜ ๋ณ€ํ™”, ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค, ๊ทผ์›์„ฌ์œ ์˜ ์ด์ƒ๊ณผ ์‚ฌ๋ฆฝ์ฒด์˜ ๋ณ€ํ™” ๊ทธ๋ฆฌ๊ณ  ๊ทผ์„ฌ์œ ๋‚ด ๊ตฌ์กฐ์ด์ƒ ๋“ฑ์ด๋‹ค. ์ด๋Ÿฌํ•œ ์†Œ๊ฒฌ๋“ค์€ ํŠน์ • ์งˆํ™˜์— ๊ตญํ•œ๋˜์–ด ๊ด€์ฐฐ๋˜๊ธฐ๋ณด๋‹ค๋Š” ์—ฌ๋Ÿฌ ์งˆํ™˜์—์„œ ๊ณตํ†ต์ ์œผ๋กœ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋Œ€๋ถ€๋ถ„์ด๋‹ค. ๋”ฐ๋ผ์„œ, ๋ณธ๋ฌธ์—์„œ๋Š” ๊ทผ์œก์กฐ์ง์—์„œ ์ด๋Ÿฌํ•œ ์†Œ๊ฒฌ๋“ค์„ ๊ด€์ฐฐํ•˜์˜€์„ ๋•Œ ์–ด๋–ป๊ฒŒ ํ•ด์„ํ•˜๊ณ  ์ง„๋‹จ์— ์‘์šฉํ•  ๊ฒƒ์ธ์ง€์— ๋Œ€ํ•ด ๋‹ค๋ฃจ์–ด ๋ณผ ๊ฒƒ์ด๋‹ค.
๋ณธ ๋ก 
๋ณธ ๋ก 
1. ๊ทผ์ƒ๊ฒ€๊ณผ ์กฐ์ง์—ผ์ƒ‰
1. ๊ทผ์ƒ๊ฒ€๊ณผ ์กฐ์ง์—ผ์ƒ‰
์„œ๋ก ์—์„œ ๊ธฐ์ˆ ํ•œ ๋ฐ”์™€ ๊ฐ™์ด ๊ทผ์œก๋ณ‘์˜ ๊ณตํ†ต๋œ ์ž„์ƒ ์ฆ์ƒ์€ ๊ทผ์‡ ์•ฝ์ด๋ฏ€๋กœ ์‹ ๊ฒฝ๊ณ„์ง„์ฐฐ, ์‹ ๊ฒฝ์ „๋„๊ฒ€์‚ฌ์™€ ์นจ๊ทผ์ „๋„๊ฒ€์‚ฌ, ํ˜ˆ์•ก๊ฒ€์‚ฌ๋ฅผ ํ†ตํ•ด ๋จผ์ € ๊ทผ์‡ ์•ฝ์ด ๊ทผ์œก์—์„œ ๊ธฐ์ธํ•˜๋Š”์ง€๋ฅผ ํŒ๋‹จํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”ํ•˜๋‹ค. ๊ทผ์ƒ๊ฒ€์„ ๊ฒฐ์ •ํ•œ ํ›„์—๋Š” ์ƒ๊ฒ€ํ•  ๊ทผ์œก์„ ์„ ํƒํ•ด์•ผ ํ•˜๋Š”๋ฐ, ์ด ๋•Œ ๊ทผ์œก์˜์ƒ๊ฒ€์‚ฌ๊ฐ€ ๋„์›€์ด ๋œ๋‹ค. ๊ทผ์œก์˜ ์ปดํ“จํ„ฐ๋‹จ์ธต์ดฌ์˜ ๋˜๋Š” ์ž๊ธฐ๊ณต๋ช…์˜์ƒ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜์—ฌ ๊ทผ์œ„์ถ•์ด ์•„์ฃผ ๊ฒฝ๋ฏธํ•˜๊ฑฐ๋‚˜ ๋„ˆ๋ฌด ์‹ฌํ•œ ๊ทผ์œก์„ ๋ฐฐ์ œํ•˜๋Š” ๊ฒƒ์ด ์ข‹๋‹ค. ๊ทธ๋ ‡์ง€ ์•Š์œผ๋ฉด ๊ทผ์ƒ๊ฒ€์„ ํ†ตํ•ด ์–ป์„ ์ˆ˜ ์žˆ๋Š” ์ •๋ณด๊ฐ€ ์ œํ•œ๋˜๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. ๋˜ํ•œ, ์นจ๊ทผ์ „๋„๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ ๊ทผ์œก์€ ๊ฒ€์‚ฌ์— ์˜ํ•œ ์ด์ฐจ์ ์ธ ๋ณ€ํ™”๊ฐ€ ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์—ญ์‹œ ๋ฐฐ์ œํ•˜๋Š” ๊ฒƒ์ด ์ข‹๋‹ค. ์ด๋Ÿฌํ•œ ์กฐ๊ฑด์„ ๋งŒ์กฑํ•  ๊ฒฝ์šฐ ์œ„ํŒ”๋‘๊ฐˆ๋ž˜๊ทผ(biceps brachii)์„ ์„ ํƒํ•˜๋Š” ๊ฒƒ์ด ๊ฐ€์žฅ ์ข‹์€๋ฐ ์ด ๊ทผ์œก์€ ๊ทผ์„ฌ์œ ์˜ ์ฃผํ–‰๋ฐฉํ–ฅ์ด ํ‰ํ–‰ํ•˜๊ณ  ๊ทผ์„ฌ์œ ์˜ ๋น„์œจ์ด ์ž˜ ์•Œ๋ ค์ ธ ์žˆ์–ด ์งˆํ™˜์— ์˜ํ•œ ๋ณ€ํ™”๋ฅผ ํŒ๋‹จํ•˜๊ธฐ ์šฉ์ดํ•˜๋ฉฐ, ์ฒด์ค‘์˜ ๋ถ€๋‹ด์ด ์ ์–ด ์ƒ๊ฒ€ ํ›„ ๋ถˆํŽธ๊ฐ์„ ์ตœ์†Œํ™”ํ•  ์ˆ˜ ์žˆ๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค.
์ƒ๊ฒ€ํ•œ ๊ทผ์œก์กฐ์ง์€ ์•กํ™”์งˆ์†Œ์— ์˜ํ•ด ๋ƒ‰๊ฐ๋œ ์ด์†ŒํŽœํƒ„(isopentane)์„ ์ด์šฉํ•˜์—ฌ ๊ธ‰์† ๋ƒ‰๊ฐ์„ ํ•ด์•ผ ์กฐ์ง ๋‚ด์— ์–ผ์Œ๊ฒฐ์ •(ice crystal)์ด ์ƒ๊ธฐ๋Š” ๊ฒƒ์„ ๋ง‰์„ ์ˆ˜ ์žˆ๋‹ค. ๋ƒ‰๊ฐ๋œ ์กฐ์ง์€ -80โ„ƒ ์ดํ•˜์˜ ๊ธ‰์†๋ƒ‰๋™๊ณ (deep freezer)์— ๋ณด๊ด€ํ•˜๊ณ  -20โ„ƒ ์ดํ•˜์˜ ์ €์˜จ์œ ์ง€์žฅ์น˜(cryostat) ๋‚ด์—์„œ ์ ˆ๋‹จํ•˜์—ฌ ์—ผ์ƒ‰์— ํ•„์š”ํ•œ ์ ˆํŽธ(section)์„ ๋งŒ๋“ ๋‹ค[1].
๊ทผ์œก์กฐ์ง์˜ ๋ณ€ํ™”๋ฅผ ๊ด€์ฐฐํ•˜๊ธฐ ์œ„ํ•œ ์—ผ์ƒ‰๋ฒ•์€ ํฌ๊ฒŒ ์กฐ์ง์—ผ์ƒ‰(histological stain), ์กฐ์งํ™”ํ•™์—ผ์ƒ‰(histochemical stain)๊ณผ ๋ฉด์—ญ์กฐ์งํ™”ํ•™์—ผ์ƒ‰(immunohistochemical stain)์œผ๋กœ ๋‚˜๋ˆˆ๋‹ค[1]. ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰(hematoxylin and eosin stain)๊ณผ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰(Gomori-trichrome stain)์ด ์กฐ์ง์—ผ์ƒ‰์— ํ•ด๋‹นํ•˜๋ฉฐ ๊ทผ์œก์กฐ์ง์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ๊ธฐ๋ณธ์ ์ธ ๊ตฌ์กฐ์˜ ๋ณ€ํ™”๋ฅผ ํ™•์ธํ•  ์ˆ˜ ์žˆ๋Š” ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์—ผ์ƒ‰๋ฒ•์ด๋‹ค. ์กฐ์งํ™”ํ•™์—ผ์ƒ‰์€ ๊ทผ์„ฌ์œ  ๋‚ด์— ์กด์žฌํ•˜๋Š” ๋ฌผ์งˆ๋“ค์˜ ํ™”ํ•™ ๋ณ€ํ™”๋ฅผ ์ด์šฉํ•œ ์—ผ์ƒ‰์ด๋ฉฐ, ๊ทผ์›์„ฌ์œ ์˜ ๊ทธ๋ฌผ๋ง์กฐ์ง์„ ๋ฐ˜์˜ํ•˜๋Š” ๋‹ˆ์ฝ”ํ‹ด์•„๋งˆ์ด๋“œํƒˆ์ˆ˜์†Œํšจ์†Œํ…ŒํŠธ๋ผ์กธ๋ฅจํ™˜์›ํšจ์†Œ(nicotinamide dehydrogenase tetrazolium-reductase, NADH-TR)์—ผ์ƒ‰, ์‚ฌ๋ฆฝ์ฒด์˜ ๋ณ€ํ™”๋ฅผ ๋ฐ˜์˜ํ•˜๋Š” ์„์‹ ์‚ฐ์—ผํƒˆ์ˆ˜์†Œํšจ์†Œ(succinate dehydrogenase, SDH)์™€ ์‚ฌ์ดํ† ํฌ๋กฌc์‚ฐํ™”ํšจ์†Œ(cytochrome c oxidase, COX)์—ผ์ƒ‰, ์‹œ์•ฝ์˜ ์ˆ˜์†Œ์ด์˜จ๋†๋„(pH)์— ๋”ฐ๋ผ ๊ทผ์„ฌ์œ ์˜ ์œ ํ˜•์„ ๊ตฌ๋ณ„ํ•  ์ˆ˜ ์žˆ๋Š” ์•„๋ฐ๋…ธ์‹ ์ธ์‚ฐ์—ผ๋ถ„ํ•ดํšจ์†Œ(adenosine phosphatase, ATPase)์—ผ์ƒ‰์ด ์ด์— ํ•ด๋‹นํ•œ๋‹ค. ์ด์™ธ์— ์‚ฐ์„ฑ์ธ์‚ฐ์—ผ(acid phosphatase)์—ผ์ƒ‰์€ ๋Œ€์‹์„ธํฌ์˜ ํ™œ์„ฑ์„ ๋ฐ˜์˜ํ•˜๋ฉฐ, ๊ณผ์•„์ด์˜ค๋“œ์‚ฐ์‹œํ”„(periodic acid schiff, PAS)์—ผ์ƒ‰์€ ๊ทผ์„ฌ์œ  ๋‚ด ๋‹น์›์˜ ์ถ•์ ์„, ๊ทธ๋ฆฌ๊ณ  oil red O์—ผ์ƒ‰์€ ์ง€๋ฐฉ์งˆ์˜ ์ถ•์ ์„ ๋ฐ˜์˜ํ•œ๋‹ค. ๋ฉด์—ญ์กฐ์งํ™”ํ•™์—ผ์ƒ‰์€ ๊ทผ์œก์กฐ์ง ๋‚ด์— ์กด์žฌํ•˜๋Š” ํŠน์ • ๋‹จ๋ฐฑํ•ญ์›์— ๋Œ€ํ•œ ํ•ญ์›-ํ•ญ์ฒด ๋ฐ˜์‘์„ ์ด์šฉํ•œ ์—ผ์ƒ‰์ด๋ฉฐ, ์ฃผ๋กœ ํ•ญ์›์ด ๋˜๋Š” ๋‹จ๋ฐฑ์งˆ์—๋Š” ์—ผ์ฆ์— ๊ด€์—ฌํ•˜๋Š” ์ฃผ์กฐ์ง์ ํ•ฉ๋ณตํ•ฉ์ฒด(major histocompatibility complex, MHC), ์‚ฌ๋žŒ๋ฐฑํ˜ˆ๊ตฌํ•ญ์›(human leukocyte antigen, HLA)๊ณผ ๋ง‰๊ณต๊ฒฉ๋ณตํ•ฉ์ฒด(membrane attack complex, MAC) ๊ทธ๋ฆฌ๊ณ  ๊ทผ์œก์„ธํฌ๋ง‰(sarcolemma)์ด๋‚˜ ์„ธํฌ๋ฐ”๊นฅ๋ฐ”ํƒ•์งˆ(extracellular matrix)์— ์กด์žฌํ•˜๋Š” ๋‹จ๋ฐฑ์งˆ๋กœ์„œ ๋””์ŠคํŠธ๋กœํ•€(dystrophin), ๋””์ŠคํŽ„๋ฆฐ(dysferlin), ๋ฉ”๋กœ์‹ (merosin) ๋“ฑ์ด ์žˆ๋‹ค. ์—ผ์ฆ ๊ด€๋ จ ํ•ญ์›์— ๋Œ€ํ•œ ๋ฉด์—ญ์กฐ์งํ™”ํ•™์—ผ์ƒ‰์€ ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘(idiopathic inflammatory myopathy)์˜ ์ง„๋‹จ์— ๋„์›€์ด ๋œ๋‹ค. ์„ธํฌ๋ง‰๊ณผ ์„ธํฌ๋ฐ”๊นฅ๋ฐ”ํƒ•์งˆ์˜ ๋‹จ๋ฐฑ์งˆ์€ ์ฃผ๋กœ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(muscular dystrophy)์˜ ์›์ธ์ด ๋˜๋Š” ๋‹จ๋ฐฑ์งˆ์ด๋ฏ€๋กœ ์ด์— ๋Œ€ํ•œ ๋ฉด์—ญ์กฐ์งํ™”ํ•™์—ผ์ƒ‰์€ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ๊ฐ๋ณ„์ง„๋‹จ์— ํฐ ์—ญํ• ์„ ํ•˜๊ฒŒ ๋œ๋‹ค[1,2].
2. ์ •์ƒ ๊ทผ์œก์˜ ๊ตฌ์กฐ
2. ์ •์ƒ ๊ทผ์œก์˜ ๊ตฌ์กฐ
ํ•˜๋‚˜์˜ ๊ทผ์„ฌ์œ ๋Š” ๊ทผ์œก์†๋ง‰(endomysium)์— ๋‘˜๋Ÿฌ์‹ธ์—ฌ ์žˆ์œผ๋ฉฐ, ์—ฌ๋Ÿฌ ๊ฐœ์˜ ๊ทผ์„ฌ์œ ๊ฐ€ ๋ชจ์—ฌ ํ•˜๋‚˜์˜ ๊ทผ์œก๋‹ค๋ฐœ(fascicle)์„ ์ด๋ฃจ๋Š”๋ฐ ์ด๋Š” ๊ทผ์œก๋‹ค๋ฐœ๋ง‰(perimysium)์— ์˜ํ•ด ๊ตฌ๋ถ„๋œ๋‹ค. ํ•˜๋‚˜์˜ ๊ทผ์œก์€ ์—ฌ๋Ÿฌ ๊ฐœ์˜ ๊ทผ์œก๋‹ค๋ฐœ๋กœ ๊ตฌ์„ฑ๋˜๋ฉฐ ๊ทผ์œก๋ฐ”๊นฅ๋ง‰(epimysium)์— ์˜ํ•ด ๋‘˜๋Ÿฌ์‹ธ์—ฌ ์žˆ๋‹ค. ๋ณดํ†ต ํ•˜๋‚˜์˜ ๊ทผ์œก ์ ˆํŽธ์—์„œ๋Š” ๊ทผ์„ฌ์œ ์™€ ๊ทผ์œก์†๋ง‰์„ ์ฃผ๋กœ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๊ทผ์œก๋‹ค๋ฐœ๋ง‰๊ณผ ๊ทผ์œก๋‹ค๋ฐœ๋ง‰์— ํฌํ•จ๋œ ํ˜ˆ๊ด€, ์‹ ๊ฒฝ ๋“ฑ์ด ํ•จ๊ป˜ ๊ด€์ฐฐ๋˜๊ธฐ๋„ ํ•œ๋‹ค. ์ •์ƒ ๊ทผ์„ฌ์œ ์˜ ํฌ๊ธฐ๋Š” ์„ฑ์ธ์—์„œ 40-80 ฮผm์ด๋ฉฐ, ๋‹ค๊ฐํ˜• ๋ชจ์–‘์— ๊ทผ์„ฌ์œ  ๊ฐ€์žฅ์ž๋ฆฌ์— ์œ„์น˜ํ•œ ์—ฌ๋Ÿฌ ๊ฐœ์˜ ํ•ต์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค. ๊ฐ๊ฐ์˜ ๊ทผ์„ฌ์œ  ์‚ฌ์ด์˜ ๊ณต๊ฐ„์„ ๊ฒฐํ•ฉ์กฐ์ง์ด ์ฑ„์šฐ๊ณ  ์žˆ๋Š”๋ฐ ์ •์ƒ ๊ทผ์œก์—์„œ๋Š” ๊ทธ ์–‘์ด ๋งค์šฐ ์ ๋‹ค[3]. ์ด์™€ ๊ฐ™์€ ๊ทผ์„ฌ์œ ์˜ ๊ธฐ๋ณธ์ ์ธ ๊ตฌ์กฐ๋Š” ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰๊ณผ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ๊ฐ€์žฅ ์ž˜ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 1-A, B). ์ •์ƒ ๊ทผ์œก์„ธํฌ์งˆ(sarcoplasm)์€ NADH-TR, SDH ๊ทธ๋ฆฌ๊ณ  COX์—ผ์ƒ‰์—์„œ ๊ท ์งˆํ•˜๊ฒŒ ์—ผ์ƒ‰์ด ๋œ๋‹ค. ์ •์ƒ ๊ทผ์œก์—์„œ๋Š” 1ํ˜•๊ณผ 2ํ˜• ๊ทผ์„ฌ์œ ๊ฐ€ ์ผ์ •ํ•œ ๋น„์œจ์„ ์œ ์ง€ํ•˜๋ฉฐ, ๊ฐ™์€ ์„ฌ์œ ํ˜•๋ผ๋ฆฌ ์„œ๋กœ ์ธ์ ‘ํ•˜์ง€ ์•Š๊ณ  ๋ฐ”๋‘‘ํŒ๋ชจ์–‘์œผ๋กœ ๋ฐฐ์—ด๋œ๋‹ค. ์ด ํ˜•ํƒœ๋Š” ATPase์—ผ์ƒ‰์—์„œ ์ž˜ ๋‚˜ํƒ€๋‚œ๋‹ค. ATPase์—ผ์ƒ‰์€ pH 4.3์—์„œ 1ํ˜• ๊ทผ์„ฌ์œ ๋ฅผ ์ง„ํ•˜๊ฒŒ ์—ผ์ƒ‰ํ•˜๊ณ  pH 9.4์—์„œ๋Š” 2ํ˜• ๊ทผ์„ฌ์œ ๋ฅผ ์ง„ํ•˜๊ฒŒ ์—ผ์ƒ‰ํ•œ๋‹ค(Fig. 1-C, D). ์ด๊ฒƒ์€ 1ํ˜• ๊ทผ์„ฌ์œ ๊ฐ€ ์‚ฐํ™”๋Œ€์‚ฌ(oxidative metabolism)๋ฅผ ํ•˜๊ณ  2ํ˜• ๊ทผ์„ฌ์œ ๋Š” ๋‹น๋ถ„ํ•ด๋Œ€์‚ฌ(glycolytic metabolism)๋ฅผ ํ•˜๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. 2ํ˜• ๊ทผ์„ฌ์œ ๋Š” ๋‹ค์‹œ 2Aํ˜•๊ณผ 2Bํ˜•์œผ๋กœ ๋‚˜๋ˆ„๋Š”๋ฐ 2Bํ˜•์€ ๋‹น๋ถ„ํ•ดํ™œ์„ฑ๊ณผ ๋”๋ถˆ์–ด ๋ถ€๋ถ„์ ์ธ ์‚ฐํ™”ํ™œ์„ฑ์„ ๊ฐ€์ง€๋ฏ€๋กœ pH 4.6์—์„œ๋Š” ์ง„ํ•˜๊ฒŒ ์—ผ์ƒ‰๋˜๋Š” 1ํ˜• ๊ทผ์„ฌ์œ ์™€ ๋ฐ๊ฒŒ ์—ผ์ƒ‰๋˜๋Š” 2Aํ˜• ๊ทผ์„ฌ์œ  ์‚ฌ์ด์— ์ค‘๊ฐ„ ์ •๋„๋กœ ์—ผ์ƒ‰๋˜๋Š” 2Bํ˜•์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค[3]. ๊ฐ ๊ทผ์œก๋งˆ๋‹ค 1ํ˜•๊ณผ 2ํ˜• ๊ทผ์„ฌ์œ ์˜ ๋น„์œจ์ด ์ผ์ •ํ•˜๊ฒŒ ์œ ์ง€๋˜๋Š”๋ฐ ๋ณ‘์  ์ƒํ™ฉ์—์„œ๋Š” ์ด๋Ÿฌํ•œ ๋น„์œจ์—๋„ ๋ณ€ํ™”๊ฐ€ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค.
3. ๊ทผ์„ฌ์œ  ํฌ๊ธฐ์™€ ๋ชจ์–‘์˜ ๋ณ€ํ™”
3. ๊ทผ์„ฌ์œ  ํฌ๊ธฐ์™€ ๋ชจ์–‘์˜ ๋ณ€ํ™”

1) ์กฐ์ง ์†Œ๊ฒฌ

1) ์กฐ์ง ์†Œ๊ฒฌ

์ •์ƒ ๋ฒ”์œ„(40-80 ฮผm)์— ๋น„ํ•ด ์ง๊ฒฝ์ด ์ž‘์•„์ง„ ๊ทผ์„ฌ์œ ๋ฅผ ์œ„์ถ•๊ทผ์„ฌ์œ (atrophic fiber), ์ •์ƒ๋ณด๋‹ค ํฐ ์„ฌ์œ ๋ฅผ ๋น„๋Œ€๊ทผ์„ฌ์œ (hypertrophic fiber)๋ผ๊ณ  ํ•œ๋‹ค. ๊ทผ์„ฌ์œ ์˜ ํฌ๊ธฐ๋Š” ๋‹จ์ˆœํžˆ ๋ถˆ์šฉ(disuse) ๋˜๋Š” ๊ณผ์šฉ(overuse)์— ์˜ํ•ด์„œ๋„ ์ž‘์•„์ง€๊ฑฐ๋‚˜ ์ปค์งˆ ์ˆ˜ ์žˆ์œผ๋ฉฐ ๊ทผ์œก๋ณ‘๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์‹ ๊ฒฝ๋ณ‘์—์„œ๋„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค. ๊ทผ์œก๋ณ‘์—์„œ๋Š” ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ๋‘ฅ๊ทผ ๋ชจ์–‘์ด๋ฉฐ ์ •์ƒ ํฌ๊ธฐ์˜ ๊ทผ์„ฌ์œ ๋‚˜ ๋น„๋Œ€๊ทผ์„ฌ์œ ์™€ ํ˜ผ์žฌ๋˜์–ด ์žˆ๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ๋ฐ˜๋ฉด, ์‹ ๊ฒฝ๋ณ‘์— ์˜ํ•œ ์œ„์ถ•๊ทผ์„ฌ์œ ๋Š” ๊ฐ์ด ์ง„ ํ˜•ํƒœ(angulated fiber)์ด๋‹ค. ๊ทผ์œก๋ณ‘๊ณผ ๋‹ฌ๋ฆฌ ์‹ ๊ฒฝ๋ณ‘์—์„œ๋Š” ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ๊ตฐ์ง‘ํ•ด ์žˆ๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์œผ๋ฉฐ ์ด๋ฅผ ์ง‘๋‹จ์œ„์ถ•(group atrophy)์ด๋ผ๊ณ  ํ•˜๊ณ , ๋‚˜์•„๊ฐ€ ๊ทผ์œก๋‹ค๋ฐœ ์ „์ฒด๊ฐ€ ์œ„์ถ•๋˜๋Š” ๊ฒƒ์„ ๋‹ค๋ฐœ์œ„์ถ•(fascicular atrophy)์ด๋ผ๊ณ  ํ•œ๋‹ค. ์ด๋Ÿฌํ•œ ์ฐจ์ด๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ๊ทผ์œก๋ณ‘๊ณผ ์‹ ๊ฒฝ๋ณ‘์— ์˜ํ•œ ๋ณ€ํ™”๋ฅผ ๊ตฌ๋ถ„ํ•  ์ˆ˜ ์žˆ๋‹ค[4].

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ์งˆํ™˜

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ์งˆํ™˜

(1) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(muscular dystrophies)
(1) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(muscular dystrophies)
๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ๊ฐ€์žฅ ์œ ๋ณ‘๋ฅ ์ด ๋†’์€ ๋’ค์„ผ๋А/๋ฒ ์ปค๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(Duchenne/Becker muscular dystrophies)์™€ ์‚ฌ์ง€๋Œ€๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(limb-girdle muscular dystrophies, LGMD), ์„ ์ฒœ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(congenital muscular dystrophies) ๊ทธ๋ฆฌ๊ณ  ์–ผ๊ตด์–ด๊นจ์œ„ํŒ”๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(facioscapulohumeral dystrophy), ๊ทผ๊ธด์žฅ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(myotonic dystrophy), ๋ˆˆ์ธ๋‘๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(oculopharyngeal muscular dystrophy), Emery-Dreifuss ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ ๋“ฑ ๋‹ค์–‘ํ•œ ์งˆํ™˜์„ ํฌํ•จํ•œ๋‹ค. ์„ ์ฒœ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ์ถœ์ƒ ์‹œ๋ถ€ํ„ฐ ์ €๊ธด์žฅ์ฆ์„ ๋‚˜ํƒ€๋‚ด๊ณ  ์šด๋™๋ฐœ๋‹ฌ์ง€์—ฐ์„ ๋ณด์ด๋Š” ์งˆํ™˜์ด์ง€๋งŒ, ์ด๋ฅผ ์ œ์™ธํ•œ ๋Œ€๋ถ€๋ถ„์˜ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ์†Œ์•„๊ธฐ๋ถ€ํ„ฐ ์„ฑ์ธ๊ธฐ์— ์ด๋ฅด๊ธฐ๊นŒ์ง€ ๋ฐœ๋ณ‘ ์—ฐ๋ น์ด ๋‹ค์–‘ํ•˜๋‹ค. ์งˆํ™˜์— ๋”ฐ๋ผ ์ฐจ์ด๊ฐ€ ์žˆ์œผ๋‚˜ ์ž„์ƒ์ ์œผ๋กœ ์‚ฌ์ง€ ๋ชธ์ชฝ๊ทผ์œก์˜ ๊ทผ๋ ฅ์ €ํ•˜์™€ ๊ทผ์œ„์ถ•์ด ๋‘๋“œ๋Ÿฌ์ง€๋ฉฐ ํ˜ˆ์ฒญ ํฌ๋ ˆ์•„ํ‹ดํ‚ค๋‚˜์•„์ œ(creatine kinase)๊ฐ€ ์ฆ๊ฐ€ํ•œ๋‹ค.
๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ์กฐ์ง ์†Œ๊ฒฌ์—์„œ ์œ„์ถ•๊ทผ์„ฌ์œ ๋Š” ๋น„๋Œ€๊ทผ์„ฌ์œ ์™€ ๋ฌด์ž‘์œ„๋กœ ํ˜ผ์žฌ๋˜์–ด ์žˆ๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค(Fig. 2-A). ๋”ฐ๋ผ์„œ ๊ทผ์„ฌ์œ ์˜ ํฌ๊ธฐ์˜ ๋‹ค์–‘์„ฑ์ด ์ฆ๊ฐ€ํ•˜๋ฉฐ ์œ ๋ณ‘ ๊ธฐ๊ฐ„์ด ๊ธธ์–ด์งˆ์ˆ˜๋ก ์ด ๋‹ค์–‘์„ฑ์€ ํ›จ์”ฌ ๋” ์ฆ๊ฐ€ํ•˜๊ฒŒ ๋œ๋‹ค[4,5]. ๋น„๋Œ€๊ทผ์„ฌ์œ ๋Š” ๋‹ค์‹œ ์ž‘์€ ํฌ๊ธฐ๋กœ ๋ถ„๋ฆฌ๋˜์–ด ๊ฐ€๋Š” ๊ณผ์ •์„ ๊ฑฐ์น˜๋ฉด์„œ ๋ถ„๋ฆฌ๊ทผ์„ฌ์œ (splitting fiber)๊ฐ€ ๋˜๊ธฐ๋„ ํ•œ๋‹ค[4]. ๊ทผ์„ฌ์œ ๊ฐ€ ๋‹ค๊ฐํ˜•์—์„œ ๋‘ฅ๊ทผ ๋ชจ์–‘์œผ๋กœ ๋ณ€ํ•จ์— ๋”ฐ๋ผ ๊ทผ์„ฌ์œ  ์‚ฌ์ด์˜ ๊ณต๊ฐ„์ด ๋„“์–ด์ง€๊ฒŒ ๋˜๊ณ  ์ด ๊ณต๊ฐ„์€ ๊ฒฐํ•ฉ์กฐ์ง์œผ๋กœ ์ฑ„์›Œ์ง€๋ฏ€๋กœ ์„ธํฌ์‚ฌ์ด์งˆ์˜ ์„ฌ์œ ํ™”(fibrosis)๋ฅผ ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 2-A). ํ›„์— ๊ธฐ์ˆ ํ•˜๊ฒŒ ๋  ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ๊ณผ ๋”๋ถˆ์–ด ์ด์™€ ๊ฐ™์€ ๊ทผ์„ฌ์œ ์˜ ์œ„์ถ•๊ณผ ๋น„๋Œ€, ์„ธํฌ์‚ฌ์ด์งˆ ์„ฌ์œ ํ™”๋Š” ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋ฅผ ๋Œ€ํ‘œํ•˜๋Š” ์กฐ์ง ์†Œ๊ฒฌ์ด๋‹ค[5].
(2) ์„ ์ฒœ๊ทผ์œก๋ณ‘(congenital myopathies)
(2) ์„ ์ฒœ๊ทผ์œก๋ณ‘(congenital myopathies)
์„ ์ฒœ๊ทผ์œก๋ณ‘์€ ์ถœ์ƒ ์งํ›„๋‚˜ ์œ ์•„๊ธฐ์— ๋ฐœ๋ณ‘ํ•˜๋ฉฐ ์‚ฌ์ง€์˜ ๊ทผ๋ ฅ์ €ํ•˜๊ฐ€ ์ฒœ์ฒœํžˆ ์ง„ํ–‰ํ•˜๊ฑฐ๋‚˜ ์ง„ํ–‰์„ ๊ฑฐ์˜ ํ•˜์ง€ ์•Š๋Š” ๊ฒฝ๊ณผ๋ฅผ ๋ณด์ด์ง€๋งŒ ์ผ๋ถ€์—์„œ๋Š” ๋ฐœ๋ณ‘ ์ดˆ๊ธฐ๋ถ€ํ„ฐ ์šด๋™๋ฐœ๋‹ฌ์˜ ์ง€์—ฐ์ด ์‹ฌ๊ฐํ•˜์—ฌ ๋…๋ฆฝ๋ณดํ–‰์„ ํ•˜์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๋„ ์žˆ๋‹ค[6]. ์•ˆ๋ฉด๊ทผ์œก๊ณผ ์™ธ์•ˆ๊ทผ์˜ ๋งˆ๋น„๊ฐ€ ํ”ํžˆ ๋™๋ฐ˜๋˜๋ฉฐ ์‹ฌํ•œ ๊ฒฝ์šฐ ์กฐ๊ธฐ์— ํ˜ธํก๊ทผ์˜ ์•ฝํ™”๋ฅผ ๋ณด์ด๊ธฐ๋„ ํ•œ๋‹ค. ํ˜ˆ์ฒญ ํฌ๋ ˆ์•„ํ‹ดํ‚ค๋‚˜์•„์ œ๋Š” ์•ฝ๊ฐ„ ์ƒ์Šนํ•˜๊ฑฐ๋‚˜ ์ •์ƒ์ธ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค.
์„ ์ฒœ๊ทผ์œก๋ณ‘์—์„œ๋Š” ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์™€ ๋‹ฌ๋ฆฌ ๋น„๋Œ€๊ทผ์„ฌ์œ ๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝ์šฐ๋Š” ๋“œ๋ฌผ๋ฉฐ ํฌ๊ธฐ๊ฐ€ ์ž‘๊ณ  ๋‘ฅ๊ทผ ๋ชจ์–‘์˜ ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ์ฃผ๋กœ ๊ด€์ฐฐ๋œ๋‹ค(Fig. 2-B). ํŠน์ง•์ ์œผ๋กœ ๊ทผ์„ฌ์œ ์˜ ์œ„์ถ•์€ ์ฃผ๋กœ 1ํ˜• ๊ทผ์„ฌ์œ ์—์„œ ๋”์šฑ ๋‘๋“œ๋Ÿฌ์ง€๋ฉฐ, 1ํ˜• ๊ทผ์„ฌ์œ ์˜ ์ˆ˜๊ฐ€ ๋งŽ์•„์ง€๋Š” ๊ฒƒ ๋˜ํ•œ ์„ ์ฒœ๊ทผ์œก๋ณ‘์˜ ๊ณตํ†ต์ ์ธ ํŠน์ง•์ด๋‹ค. ์„ ์ฒœ๊ทผ์œก๋ณ‘์— ์†ํ•˜๋Š” ๋Œ€๋ถ€๋ถ„์˜ ์งˆํ™˜๋“ค์€ ์ด์™€ ๊ฐ™์€ ๊ทผ์„ฌ์œ ์˜ ํฌ๊ธฐ ๋ณ€ํ™”๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๊ฐ ์งˆํ™˜๋งˆ๋‹ค ํŠน์ง•์ ์ธ ์กฐ์ง ์†Œ๊ฒฌ์ด ๊ด€์ฐฐ๋˜๋ฏ€๋กœ ๊ทผ์ƒ๊ฒ€์ด ์ง„๋‹จ์— ์ค‘์š”ํ•œ ์—ญํ• ์„ ํ•œ๋‹ค[6]. ๊ทธ๋Ÿฌ๋‚˜ ์„ ์ฒœ๊ทผ์œก๋ณ‘ ์ค‘ ๋‹ค๋ฅธ ์กฐ์งํ•™์  ํŠน์ง• ์—†์ด ๋‹จ์ˆœํžˆ ์ˆ˜๊ฐ€ ๋งŽ๊ณ  ํฌ๊ธฐ๊ฐ€ ์ž‘์€ 1ํ˜• ๊ทผ์„ฌ์œ ์™€ ๋น„๊ต์  ์ˆ˜๊ฐ€ ์ ๊ณ  ํฌ๊ธฐ๊ฐ€ ํฐ 2ํ˜• ๊ทผ์„ฌ์œ ๊ฐ€ ์ด์ •์ ๋ถ„ํฌ(bimodal distribution)๋ฅผ ๋ณด์ด๋Š” ์„ ์ฒœ์„ฌ์œ ํ˜•๋ถˆ๊ท ํ˜•(congenital fiber type disproportion)๊ณผ ๊ฐ™์€ ์งˆํ™˜๋„ ์žˆ๋‹ค(Fig. 2-C).
(3) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘(idiopathic inflammatory myopathies)
(3) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘(idiopathic inflammatory myopathies)
ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์€ ์ž๊ฐ€๋ฉด์—ญ๊ธฐ์ „์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ์—ผ์ฆ ๋ฐ˜์‘์œผ๋กœ ์ธํ•ด ๊ทผ์„ฌ์œ ์˜ ํŒŒ๊ดด๊ฐ€ ์ง„ํ–‰ํ•˜๋ฉฐ ์ˆ˜๊ฐœ์›”์— ๊ฑธ์ณ ์ ์ฐจ์ ์ธ ๊ทผ์‡ ์•ฝ์ด ๋ฐœ์ƒํ•˜๋Š” ์งˆํ™˜์ด๋‹ค. ์ „ํ†ต์ ์œผ๋กœ๋Š” Bohan and Peter๊ฐ€ ์ œ์‹œํ•œ ๊ธฐ์ค€์— ๊ทผ๊ฑฐํ•˜์—ฌ ๋‹ค๋ฐœ๊ทผ์—ผ(polymyositis)๊ณผ ํ”ผ๋ถ€๊ทผ์—ผ(dermatomyositis)์œผ๋กœ๋งŒ ๋ถ„๋ฅ˜๋˜์–ด ์™”์œผ๋‚˜ ์ง„๋‹จ๊ณผ ๋ณ‘๋ฆฌ๊ธฐ์ „์„ ์ดํ•ดํ•˜๋Š” ๋ฐ ํ•œ๊ณ„๊ฐ€ ์žˆ์—ˆ๋‹ค. ์ตœ๊ทผ ์ƒˆ๋กญ๊ฒŒ ์ œ์‹œ๋œ ๋ณ‘๋ฆฌ๊ธฐ์ค€๊ณผ ๋‹ค์–‘ํ•œ ๊ทผ์—ผํŠน์ดํ•ญ์ฒด(myositis-specific antibodies)์˜ ๋ฐœ๊ฒฌ์œผ๋กœ ์ƒˆ๋กœ์šด ์ง„๋‹จ ๋ฐ ๋ถ„๋ฅ˜๋ฅผ ํ•˜๊ฒŒ ๋˜์—ˆ์œผ๋ฉฐ, ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์„ ๋ฉด์—ญ๋งค๊ฐœ๊ดด์‚ฌ๊ทผ์œก๋ณ‘(immune-mediated necrotizing myopathy), ํ”ผ๋ถ€๊ทผ์—ผ(dermatomyositis), ๋ด‰์ž…์ฒด๊ทผ์—ผ(inclusion body myositis), ๋‹ค๋ฐœ๊ทผ์—ผ(polymyositis)์œผ๋กœ ๊ตฌ๋ถ„ํ•œ๋‹ค. ์ด์™€ ๋”๋ถˆ์–ด, ๋‹ค๋ฅธ ๊ทผ์—ผ์˜ ํŠน์ง•์ด ๋ฐฐ์ œ๋˜๋ฉด์„œ ๋น„ํŠน์ด์ ์ธ ๊ทผ์œก๋‹ค๋ฐœ๋ง‰ ์ฃผ๋ณ€๊ณผ ํ˜ˆ๊ด€ ์ฃผ๋ณ€์˜ ์—ผ์ฆ์„ธํฌ ์นจ์œค๋งŒ ๊ด€์ฐฐ๋˜๋Š” ๋น„ํŠน์ด๊ทผ์—ผ(nonspecific myositis)์„ ํฌํ•จํ•œ๋‹ค.
ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์—์„œ๋Š” ์—ผ์ฆ ๋ฐ˜์‘์— ์˜ํ•ด ๊ดด์‚ฌ์™€ ์žฌ์ƒ์ด ๋ฐ˜๋ณต๋˜๋Š” ๊ฒฐ๊ณผ๋กœ ๋‘ฅ๊ทผ ๋ชจ์–‘์˜ ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ๊ด€์ฐฐ๋œ๋‹ค. ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์— ๋น„ํ•ด ๋น„๋Œ€๊ทผ์„ฌ์œ ๋Š” ์ƒ๋Œ€์ ์œผ๋กœ ๋“œ๋ฌผ๊ฒŒ ๋‚˜ํƒ€๋‚˜์ง€๋งŒ, ์—ผ์ฆ๊ทผ์œก๋ณ‘์˜ ์œ ๋ณ‘ ๊ธฐ๊ฐ„์ด ๊ธด ๊ฒฝ์šฐ์—๋Š” ๋น„๋Œ€๊ทผ์„ฌ์œ ๊ฐ€ ๊ด€์ฐฐ๋˜๊ธฐ๋„ ํ•œ๋‹ค. ํŠนํžˆ ํ”ผ๋ถ€๊ทผ์—ผ์—์„œ๋Š” ๊ทผ์œก๋‹ค๋ฐœ์˜ ๊ฐ€์žฅ์ž๋ฆฌ์— ์œ„์น˜ํ•œ ๊ทผ์„ฌ์œ ์—์„œ ์œ„์ถ•์ด ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š”๋ฐ ์ด๋ฅผ ๋‹ค๋ฐœ์ฃผ๋ณ€์œ„์ถ•(perifascicular atrophy)์ด๋ผ๊ณ  ํ•˜๋ฉฐ[7] ํ”ผ๋ถ€๊ทผ์—ผ์˜ ์งˆ๋ณ‘ํŠน์œ ์ง•ํ›„(pathognomonic sign)๋ผ๊ณ  ํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 2-D). ๋˜ํ•œ, ๋ด‰์ž…์ฒด๊ทผ์—ผ์€ ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ํŠนํžˆ ์ž์ฃผ ๊ด€์ฐฐ๋˜๋Š” ์งˆํ™˜์ด๋‹ค. ์œ„์ถ•๊ทผ์„ฌ์œ ๊ฐ€ ํŠน์ง•์ ์ธ ๋ถ„ํฌ๋ฅผ ๋ณด์ด์ง€๋Š” ์•Š์œผ๋‚˜ 10-20 ฮผm ์ •๋„์˜ ๋งค์šฐ ์ž‘์€ ๊ทผ์„ฌ์œ ๋ฅผ ์ž์ฃผ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค[7].
(4) ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘(motor neuron diseases)
(4) ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘(motor neuron diseases)
์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘์€ ์šด๋™์‹ ๊ฒฝ์„ธํฌ์˜ ํ‡ดํ™”๋กœ ์ธํ•ด ๊ทผ์„ฌ์œ ์˜ ํƒˆ์‹ ๊ฒฝํ™”๊ฐ€ ์ผ์–ด๋‚˜๊ณ  ๊ฒฐ๊ณผ์ ์œผ๋กœ ๊ทผ๋ ฅ์ €ํ•˜์™€ ๊ทผ์œ„์ถ•์ด ์ง„ํ–‰ํ•˜๋Š” ๋งŒ์„ฑ ์งˆํ™˜์ด๋‹ค. ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘์—์„œ ์œ„์ถ•๊ทผ์„ฌ์œ ๋Š” ๋Œ€๋ถ€๋ถ„ ๊ฐ์ง„ ํ˜•ํƒœ๋ฅผ ๋ณด์ธ๋‹ค(Fig. 2-E). ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘์˜ ์ดˆ๊ธฐ์— ์ผ๋ถ€ ์šด๋™๋‹จ์œ„(motor unit)์˜ ํƒˆ์‹ ๊ฒฝํ™”(denervation)๊ฐ€ ๋จผ์ € ์ผ์–ด๋‚˜๋ฉด์„œ ํ•ด๋‹น๋˜๋Š” ์šด๋™๋‹จ์œ„์— ์†ํ•˜๋Š” ๊ทผ์„ฌ์œ ์˜ ์œ„์ถ•์ด ์ผ์–ด๋‚˜๊ณ  ์ดํ›„์— ์‹ ๊ฒฝ์žฌ๋ถ„ํฌ(reinnervation) ๊ณผ์ •์„ ๊ฑฐ์น˜๊ณ  ๋‹ค์‹œ ํƒˆ์‹ ๊ฒฝํ™”๊ฐ€ ์ผ์–ด๋‚˜๋Š” ๊ณผ์ •์„ ๋ฐ˜๋ณตํ•˜๋ฉด์„œ ์œ„์ถ• ๊ทผ์„ฌ์œ ๋Š” ์ ์ฐจ ๊ตฐ์ง‘ํ•˜๊ฒŒ ๋œ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋กœ ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘์˜ ๊ทผ์œก์กฐ์ง์—์„œ๋Š” ์ง‘๋‹จ์œ„์ถ•๊ณผ ๋‹ค๋ฐœ์œ„์ถ•์„ ์‰ฝ๊ฒŒ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 2-F). ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ, ์šด๋™์‹ ๊ฒฝ์„ธํฌ๋ณ‘์„ ํฌํ•จํ•œ ๋งŒ์„ฑ ์‹ ๊ฒฝ๋ณ‘์—์„œ๋Š” ํƒˆ์‹ ๊ฒฝ ๋ฐ ์‹ ๊ฒฝ์žฌ๋ถ„ํฌ ๊ณผ์ •์„ ํ†ตํ•ด ๊ฐ™์€ ์„ฌ์œ ํ˜•๋ผ๋ฆฌ ๊ตฐ์ง‘ํ•˜๋Š” โ€˜๊ทผ์„ฌ์œ ํ˜•์ง‘๋‹จํ™”(fiber type grouping)โ€™๋„ ํ•จ๊ป˜ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 2-E). ์กฐ์ง ์†Œ๊ฒฌ์—์„œ ์ง‘๋‹จ์œ„์ถ•, ๋‹ค๋ฐœ์œ„์ถ• ๋ฐ ๊ทผ์„ฌ์œ ํ˜•์ง‘๋‹จํ™”๋ฅผ ๊ด€์ฐฐํ•œ๋‹ค๋ฉด ์‹ ๊ฒฝ๋ณ‘์— ์˜ํ•œ ๊ทผ์œก์กฐ์ง์˜ ๋ณ€ํ™”๋กœ ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
4. ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ
4. ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ

1) ์กฐ์ง ์†Œ๊ฒฌ

1) ์กฐ์ง ์†Œ๊ฒฌ

๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ์€ ๋‹ค์–‘ํ•œ ๊ทผ์œก๋ณ‘์—์„œ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๋น„ํŠน์ด์ ์ธ ์†Œ๊ฒฌ์ด๋‹ค. ๊ทผ์„ฌ์œ ์˜ ์†์ƒ์„ ์ˆ˜๋ฐ˜ํ•˜๋Š” ๋ชจ๋“  ์ข…๋ฅ˜์˜ ๊ทผ์œก๋ณ‘๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์™ธ์ƒ, ํšก๋ฌธ๊ทผ์œตํ•ด์ฆ(rhabdomyolysis)์—์„œ๋„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ดด์‚ฌ๋œ ๊ทผ์„ฌ์œ ๋Š” ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰์—์„œ ์„ธํฌ์งˆ์ด ์˜…์–ด์ง„ ํ˜•ํƒœ๋กœ ๊ด€์ฐฐ๋˜๋ฏ€๋กœ ์•กํ™”์„ฌ์œ (liquefied fiber) ๋˜๋Š” ์œ ๋ฆฌ์งˆ์„ฌ์œ (hyaline fiber)๋กœ ๋ถˆ๋ฆฌ๊ธฐ๋„ ํ•œ๋‹ค(Fig. 3-A, arrows). ๊ดด์‚ฌ๋œ ๊ทผ์„ฌ์œ ๋Š” ์ฃผ๋ณ€์— ๋Œ€์‹์„ธํฌ๊ฐ€ ์ž์ฃผ ๊ด€์ฐฐ๋˜๋ฉฐ(Fig. 3-B, arrowhead) ๋”ฐ๋ผ์„œ acid phosphatase์—ผ์ƒ‰์—์„œ ํ™œ์„ฑ๋„๊ฐ€ ๋†’๊ฒŒ ๋‚˜ํƒ€๋‚˜ ๋ถ‰๊ฒŒ ์—ผ์ƒ‰๋œ๋‹ค. ์žฌ์ƒ์„ฌ์œ ๋Š” ๊ทผ์„ฌ์œ  ๊ดด์‚ฌ ํ›„ ์žฌ์ƒ๊ณผ์ •์— ์žˆ๋Š” ์„ธํฌ๋ฅผ ์ผ์ปฌ์œผ๋ฉฐ ํ™œ๋ฐœํ•œ ๋‹จ๋ฐฑ์งˆ ํ•ฉ์„ฑ์œผ๋กœ ์ธํ•ด ์„ธํฌ์งˆ์ด ํ˜ธ์—ผ๊ธฐ์„ฑ์„ ๋ ๋ฏ€๋กœ ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰์— ์˜ํ•ด ์ง™๊ฒŒ ์—ผ์ƒ‰๋˜๊ณ  ๋‚ด๋ถ€์—๋Š” ํฌ๊ธฐ๊ฐ€ ์ปค์ง„ ํ•ต์ด ๊ด€์ฐฐ๋œ๋‹ค(Fig. 3-B, arrows). ์ด๋Ÿฌํ•œ ์†Œ๊ฒฌ๋“ค์€ ์งˆํ™˜์— ๊ด€๊ณ„์—†์ด ๋งค์šฐ ์œ ์‚ฌํ•˜๋ฏ€๋กœ ๊ฐ๋ณ„์ง„๋‹จ์„ ์œ„ํ•ด์„œ๋Š” ์ž„์ƒ์ •๋ณด์™€ ๋™๋ฐ˜๋˜๋Š” ๋‹ค๋ฅธ ์กฐ์ง ์†Œ๊ฒฌ์„ ํ•จ๊ป˜ ๊ณ ๋ คํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค[4,5].

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

(1) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
(1) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ์ด ๊ด€์ฐฐ๋˜๋Š” ๋Œ€ํ‘œ์ ์ธ ๊ทผ์œก์งˆํ™˜์ด๋‹ค. ๋Œ€๋ถ€๋ถ„์˜ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ตฌ์กฐ์— ๊ด€์—ฌํ•˜๋Š” ์„ธํฌ๋ง‰ ๋‹จ๋ฐฑ์งˆ์˜ ๊ฒฐํ•์— ์˜ํ•ด ๋ฐœ์ƒํ•œ๋‹ค. ๋’ค์„ผ๋А/๋ฒ ์ปค๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๊ฐ€ ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ธ๋ฐ ์›์ธ์ด ๋˜๋Š” ๋””์ŠคํŠธ๋กœํ•€ ๋‹จ๋ฐฑ์งˆ์€ ์„ธํฌ๋ง‰๊ณผ ์„ธํฌ๋‚ด ๊ณจ๊ฒฉ์„ ์—ฐ๊ฒฐํ•˜๋Š” ์ง€์ง€๋Œ€ ์—ญํ• ์„ ํ•œ๋‹ค. ๋”ฐ๋ผ์„œ X์—ผ์ƒ‰์ฒด์— ์กด์žฌํ•˜๋Š” ๋””์ŠคํŠธ๋กœํ•€ ๋‹จ๋ฐฑ์งˆ์„ ์•”ํ˜ธํ™”ํ•˜๋Š” DMD ์œ ์ „์ž์— ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์žˆ๊ฒŒ ๋˜๋ฉด ๋””์ŠคํŠธ๋กœํ•€ ๋‹จ๋ฐฑ์งˆ์ด ์™„์ „ํžˆ ์†Œ์‹ค๋˜๊ณ  ์ด๋กœ ์ธํ•œ ๊ตฌ์กฐ์  ์ทจ์•ฝ์„ฑ ๋•Œ๋ฌธ์— ์ˆ˜์ถ• ๋ฐ ์ด์™„๊ณผ ๊ฐ™์€ ์ƒ๋ฆฌ์  ์ž๊ทน์— ์˜ํ•ด์„œ๋„ ๊ทผ์„ฌ์œ ๊ฐ€ ์‰ฝ๊ฒŒ ํŒŒ๊ดด๋œ๋‹ค[5,8]. ์ด๋Ÿฌํ•œ ์ด์œ ๋กœ ๋’ค์„ผ๋А/๋ฒ ์ปค๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์™€ ํ•จ๊ป˜, ๊ธฐ์ „์ด ์œ ์‚ฌํ•œ ์‚ฌ์ง€๋Œ€๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ์ด ๋นˆ๋ฒˆํ•˜๊ฒŒ ๊ด€์ฐฐ๋œ๋‹ค[9]. ๊ทผ์„ฌ์œ ์˜ ๊ตฌ์กฐ์  ์ทจ์•ฝ์€ ๊ทผ์„ฌ์œ ๋ง‰๋‹จ๋ฐฑ์งˆ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ, ํ•ต๋ง‰๋‹จ๋ฐฑ์งˆ(nuclear membrane proteins)๊ณผ ์„ธํฌ๋ฐ”๊นฅ๋ฐ”ํƒ•์งˆ๋‹จ๋ฐฑ์งˆ(extracellular matrix protein)์˜ ๊ฒฐํ•์— ์˜ํ•ด์„œ๋„ ์ดˆ๋ž˜๋  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์ด๋“ค ๋ชจ๋‘๊ฐ€ ๋‹ค์–‘ํ•œ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ์›์ธ๋‹จ๋ฐฑ์งˆ์ด ๋  ์ˆ˜ ์žˆ๋‹ค[10,11]. ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ ๊ณผ์ •์ด ์žฅ๊ธฐ๊ฐ„์— ๊ฑธ์ณ ๋ฐ˜๋ณต์ ์œผ๋กœ ์ผ์–ด๋‚˜๊ฒŒ ๋˜๋ฏ€๋กœ ๊ทผ์„ฌ์œ ๊ฐ€ ์ „๋ฐ˜์ ์œผ๋กœ ๋‘ฅ๊ทผ ๋ชจ์–‘์ด ๋˜๊ณ  ๊ทผ์„ฌ์œ  ์‚ฌ์ด ๊ฒฐํ•ฉ์กฐ์ง์ด ์ฆ๊ฐ€ํ•˜๋ฉฐ, ์œ„์ถ•๊ทผ์„ฌ์œ ์™€ ๋น„๋Œ€๊ทผ์„ฌ์œ ๊ฐ€ ๋™์‹œ์— ๋‚˜ํƒ€๋‚˜ ๊ทผ์„ฌ์œ  ํฌ๊ธฐ์˜ ๋‹ค์–‘์„ฑ ์ฆ๊ฐ€๊ฐ€ ๋™๋ฐ˜๋œ๋‹ค(Fig. 3-A, B).
์ด์™€ ๊ฐ™์€ ์†Œ๊ฒฌ๋“ค์€ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋ฅผ ์ง„๋‹จํ•˜๊ธฐ ์œ„ํ•œ ์ค‘์š”ํ•œ ์กฐ์ง ์†Œ๊ฒฌ์ด์ง€๋งŒ[5,8], ์›์ธ์œ ์ „์ž์™€ ๊ด€๊ณ„์—†์ด ๋Œ€๋ถ€๋ถ„์˜ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ ๊ณตํ†ต์ ์œผ๋กœ ๊ด€์ฐฐ๋˜๋ฏ€๋กœ ๊ตฌ์ฒด์ ์ธ ์ง„๋‹จ์„ ์œ„ํ•ด์„œ๋Š” ๋ฉด์—ญ์กฐ์งํ™”ํ•™ ์—ผ์ƒ‰์„ ์ถ”๊ฐ€๋กœ ์‹œํ–‰ํ•˜๊ฑฐ๋‚˜ ์œ ์ „์ž์ง„๋‹จ์ด ํ•„์š”ํ•˜๋‹ค. ํŠนํžˆ, ๋’ค์„ผ๋А๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ๊ฒฝ์šฐ ์ถœ์ƒ ๋‚จ์•„ 3,500๋ช… ์ค‘ ํ•œ ๋ช…์ด๋ผ๋Š” ๋น„๊ต์  ๋†’์€ ๋ฐœ์ƒ๋ฅ ์„ ๋ณด์ด๋ฏ€๋กœ 3-5์„ธ์— ๊ทผ๋ ฅ์ €ํ•˜๊ฐ€ ์ง„ํ–‰ํ•˜๊ณ  ์žฅ๋”ด์ง€์˜ ๊ฑฐ์ง“๋น„๋Œ€(pseudohypertrophy)๋ฅผ ๋ณด์ด๋Š” ๋“ฑ ์ž„์ƒ ์†Œ๊ฒฌ์œผ๋กœ ์ด ์งˆํ™˜์ด ์˜์‹ฌ๋  ๋•Œ ๋Œ€๋ถ€๋ถ„ ๊ทผ์ƒ๊ฒ€์„ ์‹œํ–‰ํ•˜์ง€ ์•Š๊ณ  ๋จผ์ € DMD ์œ ์ „์ž๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜๊ฒŒ ๋œ๋‹ค.
(2) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘
(2) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘
ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์—์„œ๋Š” ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์™€ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ ๋‹ค์–‘ํ•œ ์ •๋„์˜ ๊ทผ์„ฌ์œ  ๊ดด์‚ฌ์™€ ์žฌ์ƒ์ด ๊ด€์ฐฐ๋˜๋ฉฐ ๊ดด์‚ฌ๊ทผ์„ฌ์œ ์˜ ์ฃผ๋ณ€์— ๋Œ€์‹์„ธํฌ์˜ ์นจ์œค์ด ๊ด€์ฐฐ๋˜๊ธฐ๋„ ํ•œ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์€ ๊ทผ๋””์ŠคํŠธ๋กœ ํ”ผ์— ๋น„ํ•ด ์งˆํ™˜์˜ ๊ฒฝ๊ณผ๊ฐ€ ์งง์œผ๋ฏ€๋กœ ๊ดด์‚ฌ์™€ ์žฌ์ƒ์— ์ˆ˜๋ฐ˜๋˜๋Š” ๊ฒฐํ•ฉ์กฐ์ง์˜ ์ฆ๊ฐ€๋‚˜ ๊ทผ์„ฌ์œ  ํฌ๊ธฐ์˜ ๋ณ€ํ™” ํญ์ด ์ƒ๋Œ€์ ์œผ๋กœ ์ ๋‹ค[7]. ๊ดด์‚ฌ์™€ ์žฌ์ƒ์€ ํŠนํžˆ ๋ฉด์—ญ๋งค๊ฐœ๊ดด์‚ฌ๊ทผ์œก๋ณ‘์—์„œ ๊ฐ€์žฅ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋™์‹œ์— ์‚ฐ์„ฑ์ธ์‚ฐ์—ผ๋ถ„ํ•ดํšจ์†Œ(acid phosphatase)์˜ ํ™œ์„ฑ๋„๊ฐ€ ์ƒ๋‹นํžˆ ์ฆ๊ฐ€๋œ๋‹ค(Fig. 3-C). ๋‹ค๋ฐœ๊ทผ์—ผ๊ณผ ํ”ผ๋ถ€๊ทผ์—ผ์—์„œ๋„ ๋‹ค์–‘ํ•œ ์ •๋„์˜ ๊ดด์‚ฌ ๋ฐ ์žฌ์ƒ๊ทผ์„ฌ์œ ๋ฅผ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ๋ด‰์ž…์ฒด๊ทผ์—ผ์—์„œ๋Š” ์ด๋Ÿฌํ•œ ์†Œ๊ฒฌ์ด ์ƒ๋Œ€์ ์œผ๋กœ ๋“œ๋ฌผ๊ฒŒ ๊ด€์ฐฐ๋œ๋‹ค[12]. ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์—์„œ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ์™€ ์žฌ์ƒ๋ณด๋‹ค ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์ด ๋” ํŠน์ง•์ ์ธ ์†Œ๊ฒฌ์ด๋ฉฐ ์—ผ์ฆ๊ณผ ๊ด€๋ จํ•œ ๋‚ด์šฉ์€ ์ดํ›„์— ๋‹ค๋ฃจ๋„๋ก ํ•œ๋‹ค.
5. ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค
5. ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค

1) ์กฐ์ง ์†Œ๊ฒฌ

1) ์กฐ์ง ์†Œ๊ฒฌ

์—ผ์ฆ์„ธํฌ๋Š” ๊ดด์‚ฌ๊ทผ์„ฌ์œ ์˜ ์ฃผ๋ณ€์—์„œ ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ์ด๋Š” ํŒŒ๊ดด๋œ ๊ทผ์„ฌ์œ ์˜ ํฌ์‹์ž‘์šฉ์„ ์œ„ํ•ด ๋Œ€์‹์„ธํฌ(macrophage)๊ฐ€ ์นจ์œค๋˜๊ธฐ ๋•Œ๋ฌธ์ด๋ฉฐ, ๋”ฐ๋ผ์„œ ๊ทผ์„ฌ์œ ์˜ ๊ดด์‚ฌ๋ฅผ ์ˆ˜๋ฐ˜ํ•˜๋Š” ๋Œ€๋ถ€๋ถ„์˜ ๊ทผ์œก๋ณ‘์—์„œ ์ด๋ฅผ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์€ ํŠน๋ฐœ์—ผ์ฆ ๊ทผ์œก๋ณ‘์˜ ๊ฐ€์žฅ ํŠน์ง•์ ์ธ ์กฐ์ง ์†Œ๊ฒฌ์ด๋ฉฐ ๊ดด์‚ฌ๊ทผ์„ฌ์œ ์˜ ์ฃผ๋ณ€๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๊ทผ์œก์†๋ง‰, ๊ทผ์œก๋‹ค๋ฐœ๋ง‰ ๊ทธ๋ฆฌ๊ณ  ํ˜ˆ๊ด€ ์ฃผ์œ„์—์„œ ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ์ด์™ธ์— ์ผ๋ถ€ ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ๋„ ํŠน์ง•์ ์ธ ์—ผ์ฆ ๋ฐ˜์‘์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ๊ฐ๋ณ„์ง„๋‹จ์— ์œ ์˜ํ•ด์•ผ ํ•œ๋‹ค[11]. ์—ผ์ฆ์„ธํฌ๋Š” ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰์—์„œ ์‰ฝ๊ฒŒ ํ™•์ธ์ด ๋˜์ง€๋งŒ ์ฃผ์กฐ์ง ์ ํ•ฉ๋ณตํ•ฉ์ฒด๋‚˜ ์‚ฌ๋žŒ๋ฐฑํ˜ˆ๊ตฌํ•ญ์›, ๋ง‰๊ณต๊ฒฉ๋ณตํ•ฉ์ฒด ๋“ฑ ๋ฉด์—ญ ๋ฐ˜์‘์— ๋Œ€ํ•œ ํŠน์ด ํ•ญ์ฒด๋ฅผ ์ด์šฉํ•˜์—ฌ ๋ฉด์—ญ์กฐ์งํ™”ํ•™์—ผ์ƒ‰์„ ํ•จ์œผ๋กœ์จ ๋ณด๋‹ค ๋ฏผ๊ฐํ•˜๊ฒŒ ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ๋‹ค[2].

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

(1) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘
(1) ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘
์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ธ ์งˆํ™˜์ด๋‹ค. ๊ดด์‚ฌ๊ทผ์„ฌ์œ ์˜ ์ฃผ์œ„์— ๋Œ€์‹์„ธํฌ๊ฐ€ ์นจ์œค๋˜์–ด ์žˆ๋Š” ๋ชจ์Šต์ด ๊ณตํ†ต์ ์œผ๋กœ ๊ด€์ฐฐ๋˜์ง€๋งŒ ์งˆํ™˜์— ๋”ฐ๋ผ ์—ผ์ฆ์„ธํฌ๊ฐ€ ์ฃผ๋กœ ์นจ์œค๋˜๋Š” ์žฅ์†Œ๊ฐ€ ๋‹ค๋ฅด๋‹ค. ํ”ผ๋ถ€๊ทผ์—ผ์—์„œ ์—ผ์ฆ์„ธํฌ๋Š” ๊ทผ์œก๋‹ค๋ฐœ๋ง‰๊ณผ ํ˜ˆ๊ด€ ์ฃผ๋ณ€์— ์ฃผ๋กœ ์นจ์œค๋˜๋ฉฐ(Fig. 4-A), ๊ทผ์œก์†๋ง‰์—๋Š” ์นจ์œค๋˜์ง€ ์•Š๋Š”๋‹ค. ์ด์™€ ๋‹ฌ๋ฆฌ ๋‹ค๋ฐœ๊ทผ์—ผ์—์„œ๋Š” ์—ผ์ฆ์„ธํฌ๊ฐ€ ๊ทผ์œก์†๋ง‰์— ์นจ์œค๋˜๋ฉฐ ํŠน์ง•์ ์œผ๋กœ ๋น„๊ดด์‚ฌ๊ทผ์„ฌ์œ (non-necrotic fibers) ์†์œผ๋กœ ์—ผ์ฆ์„ธํฌ๊ฐ€ ์นจํˆฌํ•˜๊ฑฐ๋‚˜ ๋˜๋Š” ๊ทธ ์ฃผ๋ณ€์„ ๋‘˜๋Ÿฌ์‹ธ๋Š” ์–‘์ƒ์„ ๋ณด์ธ๋‹ค(Fig. 4-B). ๋ด‰์ž…์ฒด๊ทผ์—ผ์—์„œ๋„ ๋‹ค๋ฐœ๊ทผ์—ผ๊ณผ ๊ฐ™์€ ์–‘์ƒ์˜ ์—ผ์ฆ์„ธํฌ ์นจ์œค์ด ๊ด€์ฐฐ๋˜๋Š”๋ฐ(Fig. 4-C, arrows), ์ด์™€ ํ•จ๊ป˜ ํ…Œ๋‘๋ฆฌ๊ณตํฌ(rimmed vacuoles)๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๊ฒƒ์ด ๋˜ํ•œ ํŠน์ง•์ด๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ํ…Œ๋‘๋ฆฌ๊ณตํฌ๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€์ง€ ์•Š๋Š” ๊ฒฝ์šฐ ์—ผ์ฆ์„ธํฌ ์นจ์œค์˜ ์œ ์‚ฌ์„ฑ์œผ๋กœ ์ธํ•ด ๋ด‰์ž…์ฒด๊ทผ์—ผ์ด ๋‹ค๋ฐœ๊ทผ์—ผ์œผ๋กœ ์˜ค์ธ๋  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์†๊ฐ€๋ฝ๊ตฝํž˜๊ทผ๊ณผ ๋ฌด๋ฆŽํ„๊ทผ์˜ ์‡ ์•ฝ๊ณผ ๊ฐ™์€ ๋ด‰์ž…์ฒด๊ทผ์—ผ์˜ ํŠน์ง•์ ์ธ ์ž„์ƒ ์ฆ์ƒ์„ ๊ณ ๋ คํ•˜์—ฌ ๊ฐ๋ณ„์ง„๋‹จ์— ์œ ์˜ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. ๋‹ค๋ฅธ ์งˆํ™˜๋“ค์˜ ํŠน์ง•๋“ค์ด ๋ฐฐ์ œ๋˜๊ณ  ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋น„ํŠน์ด์ ์œผ๋กœ ๊ทผ์œก๋‹ค๋ฐœ๋ง‰๊ณผ ํ˜ˆ๊ด€ ์ฃผ๋ณ€์— ์นจ์œค๋˜๋Š” ๊ฒฝ์šฐ ๋น„ํŠน์ด๊ทผ์—ผ์œผ๋กœ ๋ถ„๋ฅ˜ํ•œ๋‹ค. ๋ฐ˜๋ฉด, ๋ฉด์—ญ ๋งค๊ฐœ๊ดด์‚ฌ๊ทผ์œก๋ณ‘์—์„œ๋Š” ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์ด ๊ฑฐ์˜ ์—†๊ฑฐ๋‚˜ ๋งค์šฐ ๋“œ๋ฌผ๊ฒŒ ๊ด€์ฐฐ๋œ๋‹ค[12]. ์ด๋Ÿฌํ•œ ์—ผ์ฆ์„ธํฌ ์นจ์œค ์–‘์ƒ์€ ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์˜ ์ƒˆ๋กœ์šด ๋ณ‘๋ฆฌํ•™์  ๋ถ„๋ฅ˜๊ธฐ์ค€์œผ๋กœ ํฌํ•จ๋˜์–ด ์žˆ๋‹ค[12]. ์ฃผ๋กœ ์นจ์œค๋˜๋Š” ์—ผ์ฆ ์„ธํฌ๋Š” ๋ฆผํ”„๊ตฌ, ํ˜•์งˆ์„ธํฌ(plasma cell), ์กฐ์ง๊ตฌ(histiocyte) ๋“ฑ์ด๋ฉฐ ํ˜ธ์‚ฐ๊ตฌ๊ฐ€ ์นจ์œค๋˜๋Š” ๊ฒฝ์šฐ๋Š” ๊ฑฐ์˜ ์—†๋‹ค[7].
(2) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
(2) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ๋„ ๊ดด์‚ฌ๊ทผ์„ฌ์œ ์˜ ์ฃผ๋ณ€์— ๋Œ€์‹์„ธํฌ๊ฐ€ ์นจ์œค๋˜๋Š” ๊ฒƒ์„ ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ๋ฐ˜๋ฉด ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘์—์„œ์™€ ๊ฐ™์€ ๋ฆผํ”„๊ตฌ, ํ˜•์งˆ์„ธํฌ, ์กฐ์ง๊ตฌ ๋“ฑ์ด ๊ทผ์œก์†๋ง‰์ด๋‚˜ ๊ทผ์œก๋‹ค๋ฐœ๋ง‰์— ์นจ์œค๋˜๋Š” ๊ฒƒ์€ ๋งค์šฐ ๋“œ๋ฌผ๋‹ค. ํŠน์ง•์ ์œผ๋กœ ์–ผ๊ตด์–ด๊นจ์œ„ํŒ”๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์™€ ๋””์ŠคํŽ„๋ฆฐ ๋‹จ๋ฐฑ์งˆ ๊ฒฐํ•์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ์‚ฌ์ง€๋Œ€๊ทผ๋””์ŠคํŠธ๋กœํ”ผ2Bํ˜•(LGMD2B, or LGMDR2 in new nomenclature)๊ณผ ์ด์˜ ๋งž์„ฌ์œ ์ „์ž์งˆํ™˜(allelic disorder)๋กœ์จ ์›์œ„๊ทผ์œก๋ณ‘ ์ค‘ ํ•˜๋‚˜์ธ ๋ฏธ์š”์‹œ๊ทผ์œก๋ณ‘(Miyoshi myopathy)์—์„œ๋Š” ๋Œ€์‹์„ธํฌ ์™ธ์˜ ์—ผ์ฆ์„ธํฌ์˜ ์นจ์œค์ด ๋งค์šฐ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š”๋ฐ ์ด ๋•Œ๋ฌธ์— ๊ฐ„ํ˜น ์—ผ์ฆ๊ทผ์œก๋ณ‘์œผ๋กœ ์˜ค์ธ๋˜๊ธฐ๋„ ํ•œ๋‹ค[13,14]. ๋”ฐ๋ผ์„œ ์กฐ์ง ์†Œ๊ฒฌ์—์„œ ์—ผ์ฆ์„ธํฌ๊ฐ€ ๊ด€์ฐฐ๋˜๋”๋ผ๋„ ์„ฃ๋ถˆ๋ฆฌ ์—ผ์ฆ๊ทผ์œก๋ณ‘์œผ๋กœ ์ง„๋‹จํ•˜๊ธฐ๋ณด๋‹ค๋Š” ์ž„์ƒ ์ฆ์ƒ๊ณผ ๊ฒฝ๊ณผ๋ฅผ ๊ณ ๋ คํ•˜์—ฌ ์ด์™€ ๊ฐ™์€ ์งˆํ™˜์„ ๊ฐ๋ณ„ํ•˜๋Š” ๊ฒƒ์ด ๋งค์šฐ ์ค‘์š”ํ•˜๋‹ค. ์–ผ๊ตด์–ด๊นจ์œ„ํŒ”๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ๊ฒฝ์šฐ, ์ตœ๊ทผ ํŠน์ง•์ ์ธ ์ž„์ƒ ์ฆ์ƒ์— ๊ทผ๊ฑฐํ•˜์—ฌ ๊ทผ์ƒ๊ฒ€์„ ์ƒ๋žตํ•˜๊ณ  ์œ ์ „์ž์ง„๋‹จ์„ ๋จผ์ € ํ•˜๊ฒŒ ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์•„ ๋ณ‘๋ฆฌ ์†Œ๊ฒฌ์— ์˜ํ•œ ๊ฐ๋ณ„์ง„๋‹จ์˜ ์ค‘์š”๋„๋Š” ๋‹ค์†Œ ๊ฐ์†Œํ•˜์˜€๋‹ค. ์นผํŽ˜์ธ3 (calpain-3) ๋‹จ๋ฐฑ์งˆ ๊ฒฐํ•์— ์˜ํ•œ ์‚ฌ์ง€๋Œ€๊ทผ๋””์ŠคํŠธ๋กœํ”ผ 2Aํ˜•(LGMD2A, or LGMDR1 in new nomenclature)์—์„œ๋Š” ํŠน์ง•์ ์œผ๋กœ ํ˜ธ์‚ฐ๊ตฌ์˜ ์นจ์œค์ด ๊ด€์ฐฐ๋˜๊ธฐ๋„ ํ•œ๋‹ค[9].
6. ํ•ต์˜ ๋ณ€ํ™”
6. ํ•ต์˜ ๋ณ€ํ™”

1) ์กฐ์ง ์†Œ๊ฒฌ

1) ์กฐ์ง ์†Œ๊ฒฌ

์ •์ƒ ๊ทผ์„ฌ์œ ์—์„œ ํ•ต์€ ํ•˜๋‚˜์˜ ๊ทผ์„ฌ์œ ์— ๋‹ค์ˆ˜๋กœ ์กด์žฌํ•˜๋ฉฐ ๊ทผ์„ฌ์œ ๋ง‰ ๋ฐ”๋กœ ์•„๋ž˜, ๊ทผ์„ฌ์œ ์˜ ๊ฐ€์žฅ์ž๋ฆฌ์— ์œ„์น˜ํ•œ๋‹ค. ์ด์™€ ๊ตฌ๋ถ„ํ•˜์—ฌ ํ•ต์ด ๊ทผ์„ฌ์œ ์˜ ๋‚ด๋ถ€ ๋˜๋Š” ์ค‘์•™์—์„œ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝ์šฐ ๋‚ดํ•ต(internal nuclei) ๋˜๋Š” ์ค‘์‹ฌํ•ต(central nuclei)์ด๋ผ๊ณ  ํ•œ๋‹ค(Fig. 5-A). ์ •์ƒ ๊ทผ์œก์กฐ์ง์—์„œ๋„ ๋‚ดํ•ต์€ 1-3% ์ •๋„์˜ ๊ทผ์„ฌ์œ ์—์„œ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ๋‚ดํ•ต์€ ๋ณ‘์ ์ธ ์ƒํ™ฉ์—์„œ ์ฆ๊ฐ€ํ•˜๋Š”๋ฐ ๋Œ€ํ‘œ์ ์ธ ๊ฒฝ์šฐ๊ฐ€ ์žฌ์ƒ๊ทผ์„ฌ์œ ์ด๋‹ค. ์žฌ์ƒ๊ทผ์„ฌ์œ ์—์„œ๋Š” ํ•ต์ด ๋‚ด๋ถ€์— ์œ„์น˜ํ•˜๋ฉฐ ํ™œ๋ฐœํ•œ ๋‹จ๋ฐฑ์งˆ ํ•ฉ์„ฑ์œผ๋กœ ์ธํ•ด ํฌ๊ธฐ๊ฐ€ ์ปค์ ธ ์žˆ๋‹ค. ํ•œํŽธ, ์—ฌ๋Ÿฌ ๊ฐœ์˜ ํ•ต์ด ๋ฉ์–ด๋ฆฌ๋ฅผ ์ด๋ฃจ๊ณ  ์žˆ๋Š” ๊ฒƒ์„ ํ•ต์‘๊ดด(nuclear clumps)๋ผ๊ณ  ํ•œ๋‹ค(Fig. 5-B, arrows). ์ด๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ทน๋‹จ์ ์ธ ์œ„์ถ•์œผ๋กœ ์ธํ•ด ์„ธํฌ์งˆ์ด ๊ฑฐ์˜ ์†Œ์‹ค๋˜๊ณ  ํ•ต๋“ค๋งŒ ๋‚จ์•„์žˆ๋Š” ์ƒํƒœ์—์„œ ๊ด€์ฐฐ๋˜๋Š” ํ˜„์ƒ์ด๋‹ค. ๊ทผ์œก์กฐ์ง์˜ ์„ธ๋กœ๋‹จ๋ฉด(longitudinal section)์—์„œ ์—ฌ๋Ÿฌ ๊ฐœ์˜ ํ•ต์ด ์ผ๋ ฌ๋กœ ์ค„์„ ์ง€์–ด ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์„ ํ•ต์‚ฌ์Šฌ(nuclear chains)์ด๋ผ๊ณ  ํ•œ๋‹ค(Fig. 5-C). ์ด๋Š” ๋‚ดํ•ต์ด ์ฆ๊ฐ€๋˜๋Š” ๊ฒฝ์šฐ์— ํ•จ๊ป˜ ๋‚˜ํƒ€๋‚˜๋Š” ์†Œ๊ฒฌ์ด๋‹ค.

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

2) ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋Š” ๊ทผ์œก์งˆํ™˜

(1) ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘(centronuclear myopathy)๊ณผ ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘(myotubular myopathy)
(1) ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘(centronuclear myopathy)๊ณผ ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘(myotubular myopathy)
์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘๊ณผ ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘์€ ์„ ์ฒœ๊ทผ์œก๋ณ‘์— ์†ํ•˜๋Š” ์งˆํ™˜์ด๋‹ค. ๋Œ€๋ถ€๋ถ„์˜ ์„ ์ฒœ๊ทผ์œก๋ณ‘์—์„œ ๋‚ดํ•ต์˜ ์ˆ˜๋Š” ์ •์ƒ์— ๋น„ํ•ด ์ฆ๊ฐ€๋˜์–ด ์žˆ์ง€๋งŒ, ๋‚ดํ•ต ๋˜๋Š” ์ค‘์‹ฌํ•ต์ด ๊ฐ€์žฅ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” ์งˆํ™˜์€ ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘๊ณผ ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘์ด๋‹ค. ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘์€ ์œ ์•„๊ธฐ์—์„œ ์„ฑ์ธ์— ์ด๋ฅด๊ธฐ๊นŒ์ง€ ๋ฐœ๋ณ‘ ์—ฐ๋ น์ด ๋‹ค์–‘ํ•˜๋ฉฐ ์‚ฌ์ง€์˜ ๊ทผ๋ ฅ์ €ํ•˜๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์•ˆ๋ฉด๊ทผ์œก์˜ ์‡ ์•ฝ๊ณผ ์™ธ์•ˆ๊ทผ๋งˆ๋น„๊ฐ€ ์ž„์ƒ์  ํŠน์ง•์ด๋‹ค. ์›์ธ์œผ๋กœ dynamin-2 ์œ ์ „์ž(DNM2)์™€ ryanodine receptor 1 ์œ ์ „์ž(RYR1), bridging integrator 1 ์œ ์ „์ž(BIN1)๊ฐ€ ์ž˜ ์•Œ๋ ค์ ธ ์žˆ๋‹ค. ํŠนํžˆ, DNM2 ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•œ ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘์—์„œ๋Š” ๊ฑฐ์˜ ๋ชจ๋“  ๊ทผ์„ฌ์œ ์—์„œ ํ•˜๋‚˜์˜ ํ•ต์ด ๊ทผ์„ฌ์œ ์˜ ์ •์ค‘์•™์— ์œ„์น˜ํ•˜๋Š” ๊ฒƒ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 5-D) [15]. ์ด์™€ ์—ฐ๊ด€ํ•˜์—ฌ ์ด ์งˆํ™˜์˜ NADH-TR์—ผ์ƒ‰์—์„œ๋Š” ๊ทผ์œก์„ธํฌ์งˆ๊ฐ€๋‹ฅ(sarcoplasmic strand)์˜ ๋ฐฉ์‚ฌ์„ฑ ๋ฐฐ์—ด์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 5-E). X-์—ผ์ƒ‰์ฒด์— ์กด์žฌํ•˜๋Š” myotubularin 1 ์œ ์ „์ž(MTM1)์˜ ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘์€ ์ถœ์ƒ์‹œ ๊ทผ๊ธด์žฅ์ €ํ•˜์™€ ํ˜ธํก๊ณค๋ž€, ์šด๋™๋ฐœ๋‹ฌ์ง€์—ฐ ๋“ฑ์„ ๋ณด์ด๋Š” ์‹ฌ๊ฐํ•œ ์งˆํ™˜์ด๋ฉฐ ์ด ์งˆํ™˜ ์—ญ์‹œ ๊ทผ์„ฌ์œ ์˜ ์ค‘์•™์— ๋‹จ์ผ ํ•ต์ด ์œ„์น˜ํ•ด ์žˆ๋Š” ๊ฒƒ์ด ์ค‘์š”ํ•œ ์กฐ์ง ํŠน์ง•์ด๋‹ค. ์ด ์งˆํ™˜์—์„œ๋Š” ์ค‘์‹ฌํ•ต๊ทผ์œก๋ณ‘์— ๋น„ํ•ด ๊ทผ์„ฌ์œ ๊ฐ€ ๋งค์šฐ ์ž‘๊ณ  ๋‘ฅ๊ทผ ๋ชจ์–‘์ธ๋ฐ ์ด๋Ÿฌํ•œ ๋ชจ์–‘์ด ๋ฐœ์ƒ ๊ณผ์ • ์ค‘์— ์žˆ๋Š” ๊ทผ์„ธ๊ด€(myotubule)๊ณผ ์œ ์‚ฌํ•˜๋‹ค๋Š” ์  ๋•Œ๋ฌธ์— ์งˆํ™˜์˜ ์ด๋ฆ„์ด ๋ถ™์—ฌ์กŒ๋‹ค. ๋˜ํ•œ ์ด ์งˆํ™˜์˜ NADH-TR์—ผ์ƒ‰์—์„œ๋Š” ๊ทผ์„ฌ์œ ์˜ ๊ฐ€์žฅ์ž๋ฆฌ์— ์—ผ์ƒ‰์ด ๊ฒฐํ•๋˜๋Š” ์ฃผ๋ณ€๋‹ฌ๋ฌด๋ฆฌ(peripheral halo)๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค(Fig. 5-F) [16].
(2) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
(2) ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ
๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ๋„ ์ผ๋ฐ˜์ ์œผ๋กœ ๋‚ดํ•ต์„ ๊ฐ€์ง„ ๊ทผ์„ฌ์œ ์˜ ๋นˆ๋„๊ฐ€ ์ฆ๊ฐ€ํ•œ๋‹ค. ๊ทธ์ค‘์—์„œ๋„ ๊ทผ๊ธด์žฅ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์—์„œ ๋‚ดํ•ต์˜ ๋นˆ๋„๊ฐ€ ํŠนํžˆ ์ฆ๊ฐ€ํ•˜๋ฉฐ ์„ธ๋กœ๋‹จ๋ฉด์—์„œ๋Š” ํ•ต์‚ฌ์Šฌ๋„ ํ”ํžˆ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ทผ๊ธด์žฅ๋””์ŠคํŠธ๋กœํ”ผ ์ค‘ ์ถœ์ƒ ์งํ›„๋ถ€ํ„ฐ ๊ทผ๊ธด์žฅ์ €ํ•˜์™€ ํ˜ธํก๊ณค๋ž€ ๋“ฑ์˜ ์ฆ์ƒ์ด ๋‚˜ํƒ€๋‚˜๋Š” ์„ ์ฒœ๊ทผ๊ธด์žฅ๋””์ŠคํŠธ๋กœํ”ผ์˜ ์กฐ์ง ์†Œ๊ฒฌ์€ ๋งค์šฐ ์ž‘์€ ๊ทผ์„ฌ์œ ์˜ ์ค‘์•™์— ๋‚ดํ•ต ๋˜๋Š” ์ค‘์‹ฌํ•ต์ด ๊ด€์ฐฐ๋˜๋ฏ€๋กœ ์•ž์„œ ๊ธฐ์ˆ ํ•œ ๊ทผ์„ธ๊ด€ ๊ทผ์œก๋ณ‘๊ณผ ๋งค์šฐ ์œ ์‚ฌํ•˜๊ณ  ์ถœ์ƒ์‹œ ๋ณด์ด๋Š” ์ž„์ƒ ์ฆ์ƒ ๋˜ํ•œ ๋งค์šฐ ์œ ์‚ฌํ•˜๋ฏ€๋กœ ๊ฐ๋ณ„์ง„๋‹จ์— ์œ ์˜ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค[17]. ๊ทผ๊ธด์žฅ๋””์ŠคํŠธ๋กœํ”ผ๋Š” ๊ทผ์„ธ๊ด€๊ทผ์œก๋ณ‘๊ณผ ๋‹ฌ๋ฆฌ ๋ณดํ†ต์—ผ์ƒ‰์ฒด ์šฐ์„ฑ์œ ์ „์„ ํ•˜๋ฉฐ ๋ชจ๊ณ„์œ ์ „์ผ ๊ฒฝ์šฐ ์„ ์ฒœํ˜•์˜ ๋ฐœ์ƒ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’์œผ๋ฏ€๋กœ ๊ฐ€์กฑ๋ ฅ์„ ํ™•์ธํ•˜๋Š” ๊ฒƒ์ด ์ง„๋‹จ์— ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋‹ค. ์ตœ๊ทผ์—๋Š” ์ถœ์ƒ์‹œ ์„ ์ฒœ๊ทผ๊ธด์žฅ๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๊ฐ€ ์˜์‹ฌ๋˜๊ณ  ๊ฐ€์กฑ๋ ฅ์ด ์žˆ๋Š” ๊ฒฝ์šฐ DMPK ์œ ์ „์ž์˜ CTG๋ฐ˜๋ณต์—ผ๊ธฐ์„œ์—ด ํ™•์žฅ(CTG repeat expansion)์„ ํ™•์ธํ•˜๋Š” ์œ ์ „์ž๊ฒ€์‚ฌ๋ฅผ ๋จผ์ € ํ•˜๊ฒŒ ๋œ๋‹ค.
7. ์‚ฌ๋ฆฝ์ฒด์˜ ๋ณ€ํ™”
7. ์‚ฌ๋ฆฝ์ฒด์˜ ๋ณ€ํ™”

1) ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ (ragged-red fiber)

1) ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ (ragged-red fiber)

๊ทผ์œก๋ณ‘์—์„œ๋Š” ๊ทผ์„ฌ์œ  ๋‚ด์— ์กด์žฌํ•˜๋Š” ์‚ฌ๋ฆฝ์ฒด์˜ ํฌ๊ธฐ์™€ ๋ชจ์–‘์ด ๋ณ€ํ™”ํ•  ์ˆ˜ ์žˆ๋‹ค. ์‚ฌ๋ฆฝ์ฒด์˜ ๋ณ€ํ™”๋Š” ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ์‰ฝ๊ฒŒ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ SDH์™€ COX์—ผ์ƒ‰์—์„œ๋„ ์ž˜ ๊ตฌ๋ถ„๋œ๋‹ค. ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ธ ์ด์ƒ์€ ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ (ragged-red fiber)์ด๋‹ค(Fig. 6-A). ์ด๊ฒƒ์€ ๋น„์ •์ƒ์ ์ธ ์‚ฌ๋ฆฝ์ฒด๊ฐ€ ์ฆ๊ฐ€ํ•จ์— ๋”ฐ๋ผ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ ์—ผ์ƒ‰์—์„œ ์„ธํฌ์งˆ์ด ๋ถ‰์€ ๋น›์„ ๋ ๊ณ  ๋„ˆ๋œ๋„ˆ๋œํ•ด์ง„ ๋ชจ์–‘์„ ๋ณด์ด๋Š” ๊ฒƒ์„ ๋น„์œ ํ•˜์—ฌ ๋ถ™์—ฌ์ง„ ์ด๋ฆ„์ด๋‹ค[18]. ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๋Š” SDH์—ผ์ƒ‰์—์„œ ์ •์ƒ ๊ทผ์„ฌ์œ ์— ๋น„ํ•ด ์ง™๊ฒŒ ์—ผ์ƒ‰๋˜๋ฏ€๋กœ ๋ถˆ๊ท ์ผ์ฒญ์ƒ‰๊ทผ์„ฌ์œ (ragged-blue fiber)๋ผ๊ณ  ๋ถ€๋ฅธ๋‹ค(Fig. 6-B). ํ•œํŽธ, COX์—ผ์ƒ‰์˜ ์ด์ƒ ์œ ๋ฌด๋Š” ์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘์— ์†ํ•˜๋Š” ๊ฐ ์งˆํ™˜์— ๋”ฐ๋ผ ๋‹ค์–‘ํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค. ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๋Š” ์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘์—์„œ ๋งค์šฐ ๋นˆ๋ฒˆํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚˜์ง€๋งŒ ์งˆํ™˜๊ณผ ๊ด€๊ณ„์—†์ด ๊ณ ๋ น ํ™˜์ž์˜ ๊ทผ์œก์กฐ์ง์—์„œ๋„ ๊ฐ€๋” ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์ด๋ฅผ ๊ด€์ฐฐํ•˜์˜€์„ ๋•Œ ํ•ด์„์— ์œ ์˜ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค.
(1) ์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘(mitochondrial myopathy)
(1) ์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘(mitochondrial myopathy)
์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘์€ ์‚ฌ๋ฆฝ์ฒด์˜ ๋Œ€์‚ฌ์ด์ƒ์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ์œ ์ „๊ทผ์œก๋ณ‘์„ ํ†ต์นญํ•œ๋‹ค. ์ผ๋ถ€์—์„œ๋Š” ํ•ต์œ ์ „์ž์˜ ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ์‚ฌ๋ฆฝ์ฒด์งˆํ™˜์˜ ์›์ธ์ด ๋˜๊ธฐ๋„ ํ•˜๋‚˜ ๋…๋ฆฝ์ ์œผ๋กœ ์กด์žฌํ•˜๋Š” ์‚ฌ๋ฆฝ์ฒด์œ ์ „์ž์˜ ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. ๋Œ€ํ‘œ์ ์ธ ์งˆํ™˜์ด ๋งŒ์„ฑ์ง„ํ–‰์™ธ์•ˆ๊ทผ๋งˆ๋น„(chronic progressive external ophthalmoplegia, CPEO), ๋จธํ”„(myoclonic epilepsy with ragged-red fibers, MERRF) ๊ทธ๋ฆฌ๊ณ  ๋ฉœ๋ผ์Šค(mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes, MELAS)์ด๋‹ค. ์ด๋“ค ์งˆํ™˜์—์„œ๋Š” ๊ทผ์œก์กฐ์ง์—์„œ ๊ณตํ†ต์ ์œผ๋กœ ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๊ฐ€ ๋‚˜ํƒ€๋‚˜๋Š”๋ฐ CPEO์™€ MERRF์—์„œ๋Š” ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ์˜ COX์—ผ์ƒ‰์ด ๊ฒฐํ•๋˜๊ณ , MELAS์—์„œ๋Š” ์ •์ƒ์œผ๋กœ ์—ผ์ƒ‰๋˜๊ธฐ๋„ ํ•˜๊ณ  ๊ฒฐํ•๋˜๊ธฐ๋„ ํ•œ๋‹ค[18]. ์ด๋ฅผ ํ™•์ธํ•˜๊ธฐ ์œ„ํ•ด์„œ SDH์™€ COX์—ผ์ƒ‰์„ ๋™์‹œ์— ์‹œํ–‰ํ•˜๊ธฐ๋„ ํ•œ๋‹ค. ๋˜ํ•œ, CPEO์™€ MERRF์—์„œ๋Š” ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๊ฐ€ ์•„๋‹Œ ๊ทผ์„ฌ์œ ์—์„œ๋„ COX ์—ผ์ƒ‰์˜ ๊ฒฐํ•์ด ๊ด‘๋ฒ”์œ„ํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚œ๋‹ค(Fig. 6-C, asterisks). ๋”ฐ๋ผ์„œ, ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๊ฐ€ ๋นˆ๋ฒˆํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ ์‚ฌ๋ฆฝ์ฒด๊ทผ์œก๋ณ‘์„ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ SDH์™€ COX์˜ ์—ผ์ƒ‰ ์–‘์ƒ์„ ํ•จ๊ป˜ ๊ณ ๋ คํ•˜์—ฌ ์‚ฌ๋ฆฝ์ฒด ๊ทผ์œก๋ณ‘ ๊ฐ๊ฐ์„ ๊ฐ๋ณ„์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
(2) ์•ฝ๋ฌผ์œ ๋ฐœ๊ทผ์œก๋ณ‘
(2) ์•ฝ๋ฌผ์œ ๋ฐœ๊ทผ์œก๋ณ‘
Human immunodeficiency virus (HIV) ๊ฐ์—ผ์˜ ์น˜๋ฃŒ์ œ๋กœ ์‚ฌ์šฉ๋˜๋Š” zidovudine์ด๋‚˜ Bํ˜• ๊ฐ„์—ผ ์น˜๋ฃŒ์ œ๋กœ ๊ฐœ๋ฐœ๋œ ๋ฐ” ์žˆ๋Š” clevudine๊ณผ ๊ฐ™์€ ์•ฝ์ œ๋Š” ์‚ฌ๋ฆฝ์ฒด๋ฅผ ์†์ƒ์‹œํ‚ค๋ฏ€๋กœ ์ด ์•ฝ์ œ๋“ค๊ณผ ์—ฐ๊ด€๋œ ๊ทผ์œก๋ณ‘์˜ ์กฐ์ง ์†Œ๊ฒฌ์—์„œ๋Š” ๋ถˆ๊ท ์ผ์ ์ƒ‰๊ทผ์„ฌ์œ ๋ฅผ ์‰ฝ๊ฒŒ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค[19]. ๋ณ‘๋ ฅ์—์„œ ์ด๋Ÿฌํ•œ ์•ฝ๋ฌผ๋ณต์šฉ๋ ฅ์ด ์žˆ๋‹ค๋ฉด ๊ทผ์œก์กฐ์ง์—์„œ ๋ถˆ๊ท ์ผ ์ ์ƒ‰๊ทผ์„ฌ์œ ๋ฅผ ๊ด€์ฐฐํ•  ๊ฐ€๋Šฅ์„ฑ์ด ๋†’๋‹ค.

2) ์†Œ์—ฝ๊ทผ์„ฌ์œ (lobulated fiber)

2) ์†Œ์—ฝ๊ทผ์„ฌ์œ (lobulated fiber)

์†Œ์—ฝ๊ทผ์„ฌ์œ (lobulated fiber)๋Š” NADH-TR์—ผ์ƒ‰์—์„œ ๊ทผ์„ฌ์œ ์˜ ๊ฐ€์žฅ์ž๋ฆฌ๊ฐ€ ์ง™๊ฒŒ ์—ผ์ƒ‰๋˜๋ฉด์„œ ๋งˆ์น˜ ์†Œ์—ฝ(lobule) ๋ชจ์–‘์„ ๋ณด์ด๋Š” ๊ฒƒ์„ ์ผ์ปซ๋Š”๋‹ค(Fig. 6-D). ์ด๋Š” ์ฃผ๋กœ ๊ทผ์„ฌ์œ  ๊ฐ€์žฅ์ž๋ฆฌ์— ์‚ฌ๋ฆฝ์ฒด๊ฐ€ ์ถ•์ ๋˜๋ฉด์„œ ์ƒ๊ธฐ๋Š” ๋น„ํŠน์ด์ ์ธ ํ˜„์ƒ์ด๋‹ค[4]. ์†Œ์—ฝ๊ทผ์„ฌ์œ (lobulated fiber)๊ฐ€ ํŠน์ง•์ ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ์งˆํ™˜์œผ๋กœ ์นผํŽ˜์ธ3 (calpain-3) ๋‹จ๋ฐฑ์งˆ ๊ฒฐํ•์— ์˜ํ•œ ์‚ฌ์ง€๋Œ€๊ทผ๋””์ŠคํŠธ๋กœํ”ผ 2Aํ˜•์ด ๋Œ€ํ‘œ์ ์ด์ง€๋งŒ[7] ๋‹ค์–‘ํ•œ ๊ทผ์œก๋ณ‘์ด ๋งŒ์„ฑ์ ์œผ๋กœ ์ง„ํ–‰ํ•  ๋•Œ ์†Œ์—ฝ๊ทผ์„ฌ์œ (lobulated fiber)๋ฅผ ์ž์ฃผ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค.
8. ๊ทผ์›์„ฌ์œ (myofibril)์˜ ์ด์ƒ
8. ๊ทผ์›์„ฌ์œ (myofibril)์˜ ์ด์ƒ

1) ์ค‘์‹ฌํ•ต์‹ฌ(central cores)

1) ์ค‘์‹ฌํ•ต์‹ฌ(central cores)

๊ทผ์›์„ฌ์œ ๋Š” ๊ทผ์„ฌ์œ  ๋‚ด์—์„œ ๊ทœ์น™์ ์ธ ๋ง์กฐ์ง(network)์„ ํ˜•์„ฑํ•˜๊ณ  ์žˆ๋Š”๋ฐ ๋‹ค์–‘ํ•œ ๊ทผ์œก๋ณ‘์—์„œ ๋ง๊ตฌ์กฐ์˜ ๊ทผ์›์„ฌ์œ ์กฐ์ง์ด ๋‹ค์–‘ํ•œ ํ˜•ํƒœ๋กœ ์†์ƒ๋˜๊ฑฐ๋‚˜ ๋ถ•๊ดด๋  ์ˆ˜ ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ์†Œ๊ฒฌ์€ NADH-TR์—ผ์ƒ‰๊ณผ ๊ฐ™์€ ์‚ฐํ™”ํšจ์†Œ์—ผ์ƒ‰์— ์˜ํ•ด ๊ฐ€์žฅ ์ž˜ ๋“œ๋Ÿฌ๋‚œ๋‹ค. ๋Œ€ํ‘œ์ ์œผ๋กœ ์ค‘์‹ฌํ•ต์‹ฌ(central core)์€ ๊ทผ์„ฌ์œ  ๋‚ด๋ถ€์— ์‚ฐํ™”ํšจ์†Œ์—ผ์ƒ‰์ด ๊ฒฐํ•๋œ ๋‘ฅ๊ทผ ๋ชจ์–‘์˜ ์˜์—ญ์„ ์ผ์ปซ๋Š”๋‹ค(Fig. 7-A). ์ค‘์‹ฌํ•ต์‹ฌ์„ ์ „์žํ˜„๋ฏธ๊ฒฝ์œผ๋กœ ๊ด€์ฐฐํ•˜๋ฉด ํ•ด๋‹น ์˜์—ญ์—์„œ ๊ทผ์›์„ฌ์œ ์˜ ๋ฐฐ์—ด์ด ์–ด๊ธ‹๋‚˜ ์žˆ๋Š” ๊ฒƒ์„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๊ทผ์›์„ฌ์œ  ๋ฐฐ์—ด ์‚ฌ์ด์— ์กด์žฌํ•˜๋Š” ์‚ฌ๋ฆฝ์ฒด ์—ญ์‹œ ์†Œ์‹ค๋˜์–ด ์žˆ๋‹ค[20]. ์ค‘์‹ฌํ•ต์‹ฌ์ด ๊ฐ€์žฅ ์ž˜ ๊ด€์ฐฐ๋˜๋Š” ์งˆํ™˜์ด ์ค‘์‹ฌํ•ต์‹ฌ๋ณ‘(central core disease)์ด๋‹ค. ์„ ์ฒœ๊ทผ์œก๋ณ‘ ์ค‘ ํ•˜๋‚˜์— ์†ํ•˜๋ฉฐ ์ด ์งˆํ™˜์˜ ๋Œ€๋ถ€๋ถ„์ด RYR1 ์œ ์ „์ž์˜ ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•ด ๋ฐœ์ƒํ•œ๋‹ค. ์ค‘์‹ฌํ•ต์‹ฌ๋ณ‘์˜ ๊ทผ์œก ์กฐ์ง์—์„œ๋Š” ๊ด€์ฐฐ๋˜๋Š” ๊ฑฐ์˜ ๋ชจ๋“  ๊ทผ์„ฌ์œ ๊ฐ€ ๋‚ด๋ถ€์— ์ค‘์‹ฌํ•ต์‹ฌ์„ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค(Fig. 7-A). ๋”ฐ๋ผ์„œ, ์ž„์ƒ์ ์œผ๋กœ ์„ ์ฒœ๊ทผ์œก๋ณ‘์ด ์˜์‹ฌ๋˜๋Š” ํ™˜์ž์˜ ๊ทผ์œก์กฐ์ง ์†Œ๊ฒฌ์—์„œ ์ค‘์‹ฌํ•ต์‹ฌ์ด ๋†’์€ ๋นˆ๋„๋กœ ๊ด€์ฐฐ๋œ๋‹ค๋ฉด ์ผ์ฐจ์ ์œผ๋กœ RYR1 ์œ ์ „์ž๋ฅผ ๊ฒ€์‚ฌํ•ด ๋ณผ ์ˆ˜ ์žˆ๋‹ค[20].

2) ํ‘œ์ /ํ‘œ์ ๋ชจ์–‘ ๊ทผ์„ฌ์œ (target/targetoid fiber)

2) ํ‘œ์ /ํ‘œ์ ๋ชจ์–‘ ๊ทผ์„ฌ์œ (target/targetoid fiber)

ํ‘œ์ (target) ๋˜๋Š” ํ‘œ์ ๋ชจ์–‘ ๊ทผ์„ฌ์œ (targetoid fiber)๋Š” ๋Œ€์ฒด๋กœ ์ค‘์‹ฌํ•ต์‹ฌ๊ณผ ์œ ์‚ฌํ•˜๊ฒŒ ๋ณด์ด์ง€๋งŒ ์‚ฐํ™”ํšจ์†Œ์—ผ์ƒ‰์ด ๊ฒฐํ•๋œ ์˜์—ญ์˜ ๊ฐ€์žฅ์ž๋ฆฌ์— ์—ผ์ƒ‰์ด ์˜คํžˆ๋ ค ์ง™์€ ํ…Œ๋‘๋ฆฌ ์˜์—ญ์ด ์žˆ๋Š” ๊ฒƒ์ด ์ฐจ์ด์ ์ด๋ฉฐ ์ด ๋ชจ์–‘์ด ํ‘œ์ (target)๊ณผ ์œ ์‚ฌํ•˜์—ฌ ์ด๋ฆ„ ๋ถ™์—ฌ์กŒ๋‹ค(Fig. 7-B, arrow). ๊ทผ์œก๋ณ‘๋ณด๋‹ค๋Š” ๋งŒ์„ฑ์ ์ธ ์‹ ๊ฒฝ๋ณ‘์— ์˜ํ•ด ๋‚˜ํƒ€๋‚œ ๋ณ€ํ™”๋กœ ํ•ด์„ํ•œ๋‹ค.

3) ์ข€๋จน์€ ๋ชจ์–‘(moth-eaten appearance)

3) ์ข€๋จน์€ ๋ชจ์–‘(moth-eaten appearance)

๊ทผ์›์„ฌ์œ ์˜ ๋ฐฐ์—ด์ด ๋ถ€๋ถ„์ ์œผ๋กœ ์†์ƒ๋˜์–ด ์ฒฉํฌ ํ˜•ํƒœ์˜ ์—ผ์ƒ‰ ์†Œ์‹ค์ด ๋‚˜ํƒ€๋‚˜๋Š” ์–‘์ƒ์„ ์ข€๋จน์€ ๋ชจ์–‘(moth-eaten appearance)์ด๋ผ๊ณ  ํ•œ๋‹ค(Fig. 7-C, arrows). ์ด๊ฒƒ์€ ์—ผ์ฆ๊ทผ์œก๋ณ‘์—์„œ ๊ฐ€์žฅ ํ”ํžˆ ๊ด€์ฐฐ๋˜์ง€๋งŒ ๋Œ€์ฒด๋กœ ๋น„ํŠน์ด์ ์ธ ๋ณ€ํ™”์ด๋‹ค. ๋‹ค๋ฅธ ์ข…๋ฅ˜์˜ ๊ทผ์œก๋ณ‘์—์„œ๋„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ฅ˜๋งˆํ‹ฐ์Šค๋‹ค๋ฐœ๊ทผ์œกํ†ต(polymyalgia rheumatica)๊ณผ ๊ฐ™์€ ๊ทผ์œก๋ณ‘ ์ด์™ธ์˜ ์งˆํ™˜์—์„œ๋„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค.
9. ๊ทผ์„ฌ์œ ๋‚ด ๋น„์ •์ƒ ๊ตฌ์กฐ๋ฌผ
9. ๊ทผ์„ฌ์œ ๋‚ด ๋น„์ •์ƒ ๊ตฌ์กฐ๋ฌผ
๊ทผ์„ฌ์œ ์˜ ์„ธํฌ์งˆ์€ ๋Œ€์ฒด๋กœ ๊ท ์งˆํ•˜๋ฉฐ ํ•ต ์ด์™ธ์˜ ๊ทผ์„ฌ์œ  ๋‚ด๋ถ€์— ์„ธํฌ์†Œ๊ธฐ๊ด€์€ ๊ด‘ํ•™ํ˜„๋ฏธ๊ฒฝ์„ ํ†ตํ•ด์„œ๋Š” ๊ฑฐ์˜ ๊ด€์ฐฐ๋˜์ง€ ์•Š๋Š”๋‹ค. ๊ท ์งˆํ•œ ์„ธํฌ์งˆ์€ ๊ทผ์›์„ฌ์œ ์˜ ๊ทœ์น™์ ์ธ ๋ฐฐ์—ด์ด ์œ ์ง€๋˜๋Š” ๊ฒƒ์„ ์‹œ์‚ฌํ•˜๋ฏ€๋กœ ์„ธํฌ์งˆ ๋‚ด์— ๋น„์ •์ƒ๊ตฌ์กฐ๋ฌผ์ด ๊ด€์ฐฐ๋˜๋Š” ๊ฒƒ์€ ๋Œ€๊ฐœ ๋ณ‘์ ์ธ ๋ณ€ํ™”๊ฐ€ ์žˆ์Œ์„ ์˜๋ฏธํ•œ๋‹ค. ๋น„์ •์ƒ๊ตฌ์กฐ๋ฌผ์€ ์ข…๋ฅ˜์— ๋”ฐ๋ผ ํŠน์ • ์งˆํ™˜์—์„œ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝํ–ฅ์„ ๋ณด์ด๊ธฐ๋„ ํ•˜๋‚˜ ๋งŽ์€ ๊ฒฝ์šฐ ๋น„ํŠน์ด์ ์ด๋ฉฐ ๋”ฐ๋ผ์„œ ์ด๋Ÿฌํ•œ ๋ณ€ํ™”๋“ค์„ ๊ด€์ฐฐํ•˜์˜€์„ ๋•Œ ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ๋Š” ์—ฌ๋Ÿฌ ์งˆํ™˜๋“ค์— ๋Œ€ํ•œ ๊ฐ๋ณ„์ง„๋‹จ ๋˜ํ•œ ์ค‘์š”ํ•˜๋‹ค.

1) ๋„ค๋ง๋ฆฐ์ฒด(nemaline bodies)

1) ๋„ค๋ง๋ฆฐ์ฒด(nemaline bodies)

๋„ค๋ง๋ฆฐ์ฒด๋Š” ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ๊ด€์ฐฐ๋˜๋Š” ๋Œ€ํ‘œ์ ์ธ ๊ทผ์„ฌ์œ ๋‚ด ๋น„์ •์ƒ๊ตฌ์กฐ๋ฌผ์ด๋‹ค. ๋ถ‰์€ ์ƒ‰์˜ ์ž‘์€ ์ ์ด๋‚˜ ์ž‘์€ ๋ง‰๋Œ€ ๋ชจ์–‘์œผ๋กœ ๋ณด์ด๋ฉฐ ํ•˜๋‚˜์˜ ๊ทผ์„ฌ์œ  ๋‚ด์— ๋‹ค์ˆ˜๋กœ ์กด์žฌํ•œ๋‹ค(Fig. 7-D). ์ „์žํ˜„๋ฏธ๊ฒฝ์—์„œ ๋„ค๋ง๋ฆฐ์ฒด๋Š” Z-disk์™€ ์œ ์‚ฌํ•œ ๋†’์€ ์ „์ž๋ฐ€๋„๋ฅผ ๋ณด์ด๋ฏ€๋กœ ๋ณดํ†ต Z-disk์—์„œ ์œ ๋ž˜ํ•œ ๊ฒƒ์œผ๋กœ ์ƒ๊ฐํ•œ๋‹ค.
(1) ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘
(1) ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘
๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๋Œ€ํ‘œ์ ์ธ ์งˆํ™˜์€ ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘(nemaline myopathy)์ด๋‹ค. ๋‹ค์ˆ˜์˜ ๊ทผ์„ฌ์œ ๊ฐ€ ๋‚ด๋ถ€์— ๋„ค๋ง๋ฆฐ์ฒด๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ ์ด๋“ค์€ ๊ทผ์„ฌ์œ ๋ง‰ ์•„๋ž˜์— ๊ตฐ์ง‘ํ•ด ์žˆ๊ฑฐ๋‚˜ ๊ทผ์„ฌ์œ  ๋‚ด์—์„œ ๋ถˆ๊ทœ์น™์ ์œผ๋กœ ํฉ์–ด์ ธ ๊ด€์ฐฐ๋œ๋‹ค. ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘์˜ ์กฐ์ง ์†Œ๊ฒฌ์€ ๊ณ ๋ชจ๋ฆฌํŠธ๋ผ์ดํฌ๋กฌ์—์„œ ๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๊ฒƒ ์™ธ์— ํฌ๊ธฐ๊ฐ€ ์ž‘๊ณ  ๋‘ฅ๊ทผ ๋ชจ์–‘์˜ ๊ทผ์„ฌ์œ ๊ฐ€ ์ฃผ๋กœ ๊ด€์ฐฐ๋˜๋ฉฐ ํŠนํžˆ ๋„ค๋ง๋ฆฐ์ฒด๋ฅผ ๊ฐ€์ง€๊ณ  ์žˆ๋Š” ๊ทผ์„ฌ์œ ๋Š” NADH-TR์—ผ์ƒ‰์ด ๋ถˆ๊ท ์ผํ•˜๋‹ค. ATPase์—ผ์ƒ‰์—์„œ๋Š” 1ํ˜•์˜ ๊ทผ์„ฌ์œ ๊ฐ€ ์ˆ˜์ ์œผ๋กœ ์šฐ์„ธํ•˜๋ฉฐ 2ํ˜•์— ๋น„ํ•ด ์ƒ๋Œ€์ ์œผ๋กœ ํฌ๊ธฐ๊ฐ€ ์ž‘๋‹ค.
๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘์€ ์„ ์ฒœ๊ทผ์œก๋ณ‘ ์ค‘ ๊ฐ€์žฅ ์œ ๋ณ‘๋ฅ ์ด ๋†’์œผ๋ฉฐ, ํ˜„์žฌ๊นŒ์ง€ ๋ชจ๋‘ 9๊ฐœ์˜ ์›์ธ์œ ์ „์ž๊ฐ€ ๋ณด๊ณ ๋œ ๋ฐ” ์žˆ๋‹ค[21]. ์›์ธ์œ ์ „์ž์— ๋”ฐ๋ผ ๋‹ค์–‘ํ•œ ์ž„์ƒํ˜•์„ ๋ณด์ด์ง€๋งŒ, ๊ฐ€์žฅ ์ „ํ˜•์ ์ธ ์ž„์ƒํ˜•์€ ์œ ์•„๊ธฐ์— ์šด๋™ ๋ฐœ๋‹ฌ์ด ์ง€์—ฐ๋˜๋ฉฐ ์‚ฌ์ง€์˜ ๊ทผ๋ ฅ์ €ํ•˜๊ฐ€ ์•ˆ๋ฉด๊ทผ์˜ ์‡ ์•ฝ๊ณผ ์™ธ์•ˆ๊ทผ๋งˆ๋น„์™€ ๋™๋ฐ˜ํ•˜์—ฌ ๋‚˜ํƒ€๋‚œ๋‹ค[6]. ์ž„์ƒ์ ์œผ๋กœ ์„ ์ฒœ๊ทผ์œก๋ณ‘์ด ์˜์‹ฌ๋˜๋Š” ํ™˜์ž์˜ ์กฐ์ง ์†Œ๊ฒฌ์—์„œ ๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๊ด€์ฐฐ๋œ๋‹ค๋ฉด ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘์„ ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘๊ณผ ๋‹ฌ๋ฆฌ ๋Šฆ์€ ๋‚˜์ด์— ๋ฐœ์ƒํ•˜์—ฌ ์•„๊ธ‰์„ฑ ๊ฒฝ๊ณผ๋กœ ์ง„ํ–‰ํ•˜๊ณ  ์‚ฌ์ง€ ๋จผ์ชฝ๊ทผ์œก์˜ ์‡ ์•ฝ๊ณผ ํ˜ธํก๊ณค๋ž€, ์‚ผํ‚ด๊ณค๋ž€์„ ๋™๋ฐ˜ํ•˜๋Š” ์‚ฐ๋ฐœ๋Šฆ์€๋ฐœ๋ณ‘๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘(sporadic late onset nemaline myopathy, SLONM)์ด ์žˆ์–ด ๊ฐ๋ณ„์ด ํ•„์š”ํ•˜๋‹ค. ์ฃผ๋กœ ์˜๋ฏธ๋ฏธ๊ฒฐ์ •๋‹จ์„ธํฌ๊ตฐ๊ฐ๋งˆ๊ธ€๋กœ๋ถˆ๋ฆฐ๋ณ‘์ฆ(monoclonal gammopathy of undetermined significance, MGUS)์ด๋‚˜ HIV ๊ฐ์—ผ๊ณผ ์—ฐ๊ด€๋œ๋‹ค[22]. ์กฐ์ง ์†Œ๊ฒฌ์€ ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘๊ณผ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๋‹ค์ˆ˜ ๊ด€์ฐฐ๋˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค.
๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๊ด€์ฐฐ๋˜๋Š” ๋˜ ๋‹ค๋ฅธ ์งˆํ™˜์œผ๋กœ ์ค‘์‹ฌ๋ถ€๋ง‰๋Œ€(core-rod)๊ทผ์œก๋ณ‘์ด ์žˆ๋‹ค. ์„ ์ฒœ๊ทผ์œก๋ณ‘ ์ค‘์˜ ํ•˜๋‚˜๋กœ ๋งค์šฐ ๋“œ๋ฌธ ์งˆํ™˜์ด์ง€๋งŒ, NADH-TR์—ผ์ƒ‰์—์„œ๋Š” ์ค‘์‹ฌํ•ต์‹ฌ์ด ๊ทธ๋ฆฌ๊ณ  ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ๋Š” ๋„ค๋ง๋ฆฐ์ฒด๊ฐ€ ๋™์‹œ์— ๊ด€์ฐฐ๋˜๋Š” ์กฐ์ง ์†Œ๊ฒฌ์ด ํŠน์ง•์ด๋‹ค[23]. ๋ฐœ๋ณ‘ ์—ฐ๋ น์€ ์†Œ์•„๊ธฐ๋ถ€ํ„ฐ ์„ฑ์ธ์— ์ด๋ฅด๊ธฐ๊นŒ์ง€ ๋‹ค์–‘ํ•˜๋ฉฐ ์ž„์ƒ์ ์œผ๋กœ๋Š” ์ฃผ๋กœ ๋จผ์ชฝ๊ทผ์œก์˜ ์‡ ์•ฝ์„ ๋ณด์ธ๋‹ค. ์›์ธ์œ ์ „์ž๋กœ๋Š” RYR1, NEB, KBTBD13, TPM2๊ฐ€ ๋ณด๊ณ ๋œ ๋ฐ” ์žˆ๋Š”๋ฐ ์ด๋“ค์€ ์ค‘์‹ฌํ•ต์‹ฌ๋ณ‘๊ณผ ๋„ค๋ง๋ฆฐ๊ทผ์œก๋ณ‘์˜ ์›์ธ์œ ์ „์ž์™€ ๊ฒน์นœ๋‹ค.

2) ์„ธํฌ์งˆ์ฒด(cytoplasmic body)์™€ ๊ตฌํ˜•์ฒด(spheroid body)

2) ์„ธํฌ์งˆ์ฒด(cytoplasmic body)์™€ ๊ตฌํ˜•์ฒด(spheroid body)

์„ธํฌ์งˆ์ฒด(cytoplasmic body)๋Š” ๋„ค๋ง๋ฆฐ์ฒด์™€ ๋งˆ์ฐฌ๊ฐ€์ง€๋กœ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ๋ถ‰์€์ƒ‰์œผ๋กœ ์—ผ์ƒ‰๋˜์ง€๋งŒ ์ด์— ๋น„ํ•ด ํฌ๊ธฐ๊ฐ€ ํฌ๊ณ  ๋‹จ๋…์œผ๋กœ ์กด์žฌํ•˜๋Š” ๊ฒฝ์šฐ๋„ ๋งŽ๋‹ค(Fig. 7-E, arrows). ๊ตฌํ˜•์ฒด(spheroid body)๋Š” ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ์ง™์€ ๋…น์ƒ‰์œผ๋กœ ๋ณด์ด๋ฉฐ ๋„ค๋ง๋ฆฐ์ฒด๋‚˜ ์„ธํฌ์งˆ์ฒด์— ๋น„ํ•ด ํฌ๊ธฐ๊ฐ€ ํฌ๋‹ค(Fig. 7-F, arrow). ๋‘ ๊ตฌ์กฐ๋ฌผ ๋ชจ๋‘ ๋น„ํŠน์ด์  ์†Œ๊ฒฌ์œผ๋กœ ํŠน์ • ์งˆํ™˜์„ ์‹œ์‚ฌํ•˜์ง€๋Š” ์•Š์œผ๋ฉฐ ๋‹ค์–‘ํ•œ ๊ทผ์œก๋ณ‘ ๋˜๋Š” ์‹ ๊ฒฝ๋ณ‘์—์„œ๋„ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ํŠนํžˆ ๊ตฌํ˜•์ฒด๋Š” ํ‘œ์ /ํ‘œ์ ๋ชจ์–‘ ๊ทผ์„ฌ์œ (target/targetoid fiber)์˜ ์ค‘์•™์—์„œ ๊ด€์ฐฐ๋˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค.
(1) ๊ทผ์›์„ฌ์œ ๊ทผ์œก๋ณ‘(myofibrillar myopathy)
(1) ๊ทผ์›์„ฌ์œ ๊ทผ์œก๋ณ‘(myofibrillar myopathy)
๊ทผ์›์„ฌ์œ ๊ทผ์œก๋ณ‘์€ ์„ธํฌ์งˆ์ฒด, ๊ตฌํ˜•์ฒด์™€ ๊ฐ™์€ ๋‹ค์–‘ํ•œ ์„ธํฌ์งˆ๋‚ด ๋น„์ •์ƒ ๊ตฌ์กฐ๋ฌผ๋“ค์˜ ์ถ•์ ์„ ํŠน์ง•์ ์ธ ์กฐ์ง ์†Œ๊ฒฌ์œผ๋กœ ๋ณด์ด๋Š” ์งˆํ™˜๋“ค์„ ์ผ์ปซ๋Š”๋‹ค[24]. ์ด๋Ÿฌํ•œ ์งˆํ™˜๋“ค์€ ๊ณตํ†ต์ ์œผ๋กœ ๋‹จ๋ฐฑ์งˆ์˜ ์‘์ง‘์„ ์ˆ˜๋ฐ˜ํ•˜๋Š”๋ฐ ๋Œ€ํ‘œ์ ์ธ ์‘์ง‘ ๋‹จ๋ฐฑ์งˆ์ด ๋ฐ์Šค๋ฏผ(desmin)์ด๋‹ค. ๋ถ„์ž์œ ์ „ํ•™์  ๊ด€์ ์—์„œ ๊ทผ์›์„ฌ์œ ๊ทผ์œก๋ณ‘์€ ์ฃผ๋กœ Z-disk์™€ ์—ฐ๊ด€๋œ ๋‹จ๋ฐฑ์งˆ์˜ ์ด์ƒ์„ ์ดˆ๋ž˜ํ•˜๋Š” ์œ ์ „์ž๋“ค์ด ์›์ธ์ด ๋œ๋‹ค. DES (desmin ์œ ์ „์ž), CRYAB (ฮฑB-crystallin ์œ ์ „์ž), MYOT (myotilin ์œ ์ „์ž), FLNC (filamin C ์œ ์ „์ž)์™€ FHL1 (FHL1 ์œ ์ „์ž) ๋“ฑ์ด ์•Œ๋ ค์ ธ ์žˆ๋‹ค[24]. ์กฐ์ง ์†Œ๊ฒฌ์œผ๋กœ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ์„ธํฌ์งˆ์ฒด๋‚˜ ๊ตฌํ˜•์ฒด๊ฐ€ ๋‹ค์ˆ˜ ๊ด€์ฐฐ๋˜๋ฉฐ ์ด ์™ธ์—๋„ ํ…Œ๋‘๋ฆฌ๋ฅผ ๊ฐ€์ง€๊ฑฐ๋‚˜ ๊ฐ€์ง€์ง€ ์•Š๋Š” ๋‹ค์–‘ํ•œ ํ˜•ํƒœ์˜ ๊ณตํฌ๊ฐ€ ๊ด€์ฐฐ๋œ๋‹ค. ๋˜ํ•œ, ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹  ๋˜๋Š” ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ์„ธํฌ์งˆ ๋‚ด์— ์ฃผ๋ณ€๋ณด๋‹ค ๋” ์ง™๊ฒŒ ์—ผ์ƒ‰๋˜๋Š” ์˜์—ญ์ด ํ”ํžˆ ๊ด€์ฐฐ๋œ๋‹ค. ์ƒ๊ฒ€ํ•œ ๊ทผ์œก์กฐ์ง์—์„œ ๋น„ํŠน์ด์  ๊ทผ์œก๋ณ‘ ๋ณ€ํ™”์™€ ๋”๋ถˆ์–ด ์ด์™€ ๊ฐ™์€ ์†Œ๊ฒฌ๋“ค์ด ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๊ด€์ฐฐ๋œ๋‹ค๋ฉด ๊ทผ์›์„ฌ์œ ๊ทผ์œก๋ณ‘์„ ์˜์‹ฌํ•ด ๋ณผ ์ˆ˜ ์žˆ๋‹ค.

3) ํ…Œ๋‘๋ฆฌ๊ณตํฌ(rimmed vacuoles)

3) ํ…Œ๋‘๋ฆฌ๊ณตํฌ(rimmed vacuoles)

ํ…Œ๋‘๋ฆฌ๊ณตํฌ๋Š” ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ๊ณตํฌ(vacuole)์˜ ๋‚ด๋ถ€์— ์—ผ์ƒ‰์ด ์†Œ์‹ค๋˜๋ฉฐ ๊ฐ€์žฅ์ž๋ฆฌ์— ๋ถ‰์€ ํ…Œ๋‘๋ฆฌ๊ฐ€ ์žˆ๋Š” ํ˜•ํƒœ์ด๋‹ค(Fig. 7-G). ๊ฐ€์žฅ์ž๋ฆฌ์˜ ๋ถ‰์€ ํ…Œ๋‘๋ฆฌ๋Š” ์ „์žํ˜„๋ฏธ๊ฒฝ์—์„œ ์ž๊ฐ€ํฌ์‹๊ณตํฌ(autophagic vacuole)๊ฐ€ ๋ฌด๋ฆฌ์ง€์–ด ์žˆ๋Š” ํ˜•ํƒœ๋กœ ๊ด€์ฐฐ๋˜๋ฏ€๋กœ ์ž๊ฐ€ํฌ์‹์ž‘์šฉ๊ณผ ์—ฐ๊ด€๋œ ๋ณ‘๋ฆฌ๊ธฐ์ „์ด ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ์ƒ๊ฐํ•œ๋‹ค. ํ…Œ๋‘๋ฆฌ๊ณตํฌ๋Š” ๋น„๊ต์  ๋‹ค์–‘ํ•œ ๊ทผ์œก๋ณ‘์—์„œ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์ž„์ƒ ์ฆ์ƒ ๋“ฑ์„ ๊ณ ๋ คํ•˜์—ฌ ์ง„๋‹จ์— ์œ ์˜ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค.
(1) GNE๊ทผ์œก๋ณ‘
(1) GNE๊ทผ์œก๋ณ‘
GNE๊ทผ์œก๋ณ‘์€ ์‚ฌ์ง€์˜ ๋จผ์ชฝ๊ทผ์œก์—์„œ ๊ทผ์‡ ์•ฝ๊ณผ ์œ„์ถ•์ด ๋‚˜ํƒ€๋‚˜๋Š” ์›์œ„๊ทผ์œก๋ณ‘ ์ค‘์˜ ํ•˜๋‚˜๋กœ GNE ์œ ์ „์ž์˜ ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•ด ๋ฐœ์ƒํ•˜๋Š” ๋ณดํ†ต์—ผ์ƒ‰์ฒด ์—ด์„ฑ์งˆํ™˜์ด๋‹ค. GNE๊ทผ์œก๋ณ‘์˜ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ๋ณ‘๋ฆฌ ์†Œ๊ฒฌ์€ ํ…Œ๋‘๋ฆฌ๊ณตํฌ์ด๋‹ค. ๋น„์ •ํ˜•์ ์ธ ์ž„์ƒํ˜•๋„ ์ผ๋ถ€์—์„œ ๋ณด๊ณ ๋˜๊ณ  ์žˆ์œผ๋‚˜ ๋Œ€๋ถ€๋ถ„์˜ ํ™˜์ž์—์„œ๋Š” ์•ž์ •๊ฐ•๊ทผ์˜ ์‡ ์•ฝ๊ณผ ์œ„์ถ•์ด ๊ฐ€์žฅ ๋จผ์ € ๋‚˜ํƒ€๋‚˜๋ฏ€๋กœ ์ดˆ๊ธฐ์— ๋ฐœ์ฒ˜์ง์„ ๋ณด์ด๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค[25]. ์ด์— ๋น„ํ•ด, ์›์œ„๊ทผ์œก๋ณ‘์— ์†ํ•˜๋Š” ๋˜ ๋‹ค๋ฅธ ์งˆํ™˜์ธ ๋ฏธ์š”์‹œ๊ทผ์œก๋ณ‘์€ ์žฅ๋”ด์ง€๊ทผ์œก์˜ ์œ„์ถ•์ด ๋จผ์ € ๋‚˜ํƒ€๋‚˜ ๋ฐœ๋ฐ”๋‹ฅ์ชฝ๊ตฝํž˜(plantar flexion)์ด ์ดˆ๊ธฐ์— ์•ฝํ™”๋˜๋ฏ€๋กœ ์ž„์ƒ ์ฆ์ƒ์„ ํ†ตํ•œ ๊ตฌ๋ณ„์ด ๊ฐ€๋Šฅํ•˜๋‹ค. ์ด๋Ÿฌํ•œ ์ž„์ƒ์  ํŠน์ง•๊ณผ ์—ฐ๊ด€ํ•˜์—ฌ ๊ทผ์ƒ๊ฒ€ ์—ญ์‹œ ์•ž์ •๊ฐ•๊ทผ์—์„œ ์‹œํ–‰ํ•˜์˜€์„ ๋•Œ ์ „ํ˜•์ ์ธ ํ…Œ๋‘๋ฆฌ๊ณตํฌ๋ฅผ ์ž˜ ๊ด€์ฐฐํ•  ์ˆ˜ ์žˆ๋‹ค. ์ƒ๋Œ€์ ์œผ๋กœ ๋ณด์กด๋˜์–ด ์žˆ๋Š” ๋„“์ ๋‹ค๋ฆฌ๋„ค๊ฐˆ๋ž˜๊ทผ์ด๋‚˜ ์œ„ํŒ”๋‘๊ฐˆ๋ž˜๊ทผ์—์„œ ๊ทผ์ƒ๊ฒ€์„ ์‹œํ–‰ํ•˜๋Š” ๊ฒฝ์šฐ ํŠน์ง•์ ์ธ ํ…Œ๋‘๋ฆฌ๊ณตํฌ๋ฅผ ๊ด€์ฐฐํ•˜์ง€ ๋ชปํ•  ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ๊ทผ์ƒ๊ฒ€ ๋Œ€์ƒ ๊ทผ์œก์„ ์„ ํƒํ•  ๋•Œ ์œ ์˜ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. GNE๊ทผ์œก๋ณ‘์€ ๋จผ์ชฝ๊ทผ์œก์˜ ์‡ ์•ฝ์„ ๋ณด์ด๋Š” ์ž„์ƒ ์ฆ์ƒ์œผ๋กœ ์ธํ•ด ํ…Œ๋‘๋ฆฌ๊ณตํฌ์›์œ„๊ทผ์œก๋ณ‘(distal myopathy with rimmed vacuoles), ์กฐ์ง ์†Œ๊ฒฌ์ด ๋ด‰์ž…์ฒด๊ทผ์—ผ๊ณผ ์œ ์‚ฌํ•˜์—ฌ ์œ ์ „ ๋ด‰์ž…์ฒด๊ทผ์œก๋ณ‘(hereditary inclusion body myopathy) ๊ทธ๋ฆฌ๊ณ  ์งˆํ™˜์˜ ํ›„๊ธฐ์— ์ด๋ฅด๊ธฐ๊นŒ์ง€ ๋„“์ ๋‹ค๋ฆฌ๋„ค๊ฐˆ๋ž˜๊ทผ์ด ๋ณด์กด๋˜๋Š” ํŠน์ง•์— ๊ทผ๊ฑฐํ•˜์—ฌ ๋„“์ ๋‹ค๋ฆฌ๋„ค๊ฐˆ๋ž˜๊ทผ๋ณด์กด๊ทผ์œก๋ณ‘(quadriceps sparing myopathy) ์ด๋ผ๊ณ  ๋ถˆ๋ฆฌ๊ธฐ๋„ ํ•˜์˜€์œผ๋‚˜ ํ˜„์žฌ๋Š” GNE๊ทผ์œก๋ณ‘์œผ๋กœ ํ†ต์นญํ•˜๊ณ  ์žˆ๋‹ค.
(2) ๋ด‰์ž…์ฒด๊ทผ์—ผ
(2) ๋ด‰์ž…์ฒด๊ทผ์—ผ
๋ด‰์ž…์ฒด๊ทผ์—ผ์€ ์•ž์„œ ๊ธฐ์ˆ ํ•œ ํŠน๋ฐœ์—ผ์ฆ๊ทผ์œก๋ณ‘ ์ค‘ ํ•˜๋‚˜์ด๋‹ค. ์กฐ์ง ์†Œ๊ฒฌ์—์„œ๋Š” ํŠน์ง•์ ์ธ ํ…Œ๋‘๋ฆฌ๊ณตํฌ์™€ ํ•จ๊ป˜ ๊ทผ์œก์†๋ง‰์˜ ์—ผ์ฆ์„ธํฌ ์นจ์œค์ด ๊ด€์ฐฐ๋˜๋Š”๋ฐ ์—ผ์ฆ์„ธํฌ๊ฐ€ ๋น„๊ดด์‚ฌ๊ทผ์„ฌ์œ ๋ฅผ ๋‘˜๋Ÿฌ์‹ธ๊ฑฐ๋‚˜ ์นจํˆฌํ•˜๋Š” ๊ฒƒ์ด ๋˜ํ•œ ํŠน์ง•์ด๋‹ค[12]. ์ž„์ƒ์ ์œผ๋กœ ๋ด‰์ž…์ฒด๊ทผ์—ผ์€ ๋น„๊ต์  ๋Šฆ์€ ๋‚˜์ด์ธ 55์„ธ ์ด์ƒ์—์„œ ๋ฐœ๋ณ‘ํ•˜๋ฉฐ ์•ž์„œ ๊ธฐ์ˆ ํ•œ ๋ฐ”์™€ ๊ฐ™์ด ์ดˆ๊ธฐ์— ์†๊ฐ€๋ฝ๊ตฝํž˜๊ทผ(finger flexors)๊ณผ ๋„“์ ๋‹ค๋ฆฌ๋„ค๊ฐˆ๋ž˜๊ทผ(quadriceps)์˜ ์‡ ์•ฝ์ด ๋จผ์ € ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค. ํ…Œ๋‘๋ฆฌ๊ณตํฌ๊ฐ€ ์œ ์‚ฌํ•˜๊ฒŒ ๊ด€์ฐฐ๋˜๋Š” GNE๊ทผ์œก๋ณ‘ ํ™˜์ž์—์„œ ๋„“์ ๋‹ค๋ฆฌ๋„ค๊ฐˆ๋ž˜๊ทผ์ด ์ƒ๋Œ€์ ์œผ๋กœ ๋ณด์กด๋˜๋Š” ๊ฒƒ๊ณผ๋Š” ๋Œ€์กฐ์ ์ด๋ผ๊ณ  ํ•  ์ˆ˜ ์žˆ๋‹ค.
(3) ๋ˆˆ์ธ๋‘๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(oculopharyngeal muscular dystrophy)/๋ˆˆ์ธ๋‘์›์œ„๊ทผ์œก๋ณ‘(oculopharyngeal distal myopathy)
(3) ๋ˆˆ์ธ๋‘๊ทผ๋””์ŠคํŠธ๋กœํ”ผ(oculopharyngeal muscular dystrophy)/๋ˆˆ์ธ๋‘์›์œ„๊ทผ์œก๋ณ‘(oculopharyngeal distal myopathy)
๋‘ ์งˆํ™˜์€ ๋ˆˆ๊บผํ’€์ฒ˜์ง, ์™ธ์•ˆ๊ทผ์˜ ๋งˆ๋น„, ์‚ผํ‚ด๊ณค๋ž€ ์ฆ์ƒ์„ ๊ณตํ†ต์ ์œผ๋กœ ๋ณด์ด๋ฉฐ ๋ˆˆ์ธ๋‘๊ทผ๋””์ŠคํŠธ๋กœํ”ผ์˜ ๊ฒฝ์šฐ ์‚ฌ์ง€์˜ ๋ชธ์ชฝ๊ทผ๋ ฅ์ €ํ•˜๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๊ณ  ๋ˆˆ์ธ๋‘์›์œ„๊ทผ์œก๋ณ‘์€ ๋จผ์ชฝ ๊ทผ์œก์ด ๋จผ์ € ์นจ๋ฒ”๋˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค. ๋‘ ์งˆํ™˜ ๋ชจ๋‘ ๊ทผ์œก์กฐ์ง์˜ ๊ณ ๋ชจ๋ฆฌ-ํŠธ๋ผ์ดํฌ๋กฌ์—ผ์ƒ‰์—์„œ ํ…Œ๋‘๋ฆฌ๊ณตํฌ๊ฐ€ ํŠน์ง•์ ์œผ๋กœ ๊ด€์ฐฐ๋œ๋‹ค. ๋‘ ์งˆํ™˜์€ ์ž„์ƒ ์ฆ์ƒ๊ณผ ์กฐ์ง ์†Œ๊ฒฌ์ด ๋งค์šฐ ์œ ์‚ฌํ•˜์ง€๋งŒ ์œ ์ „์ ์œผ๋กœ๋Š” ์„œ๋กœ ๊ตฌ๋ณ„๋œ๋‹ค. ๋ˆˆ์ธ๋‘๊ทผ๋””์ŠคํŠธ๋กœํ”ผ๋Š” PABPN1 ์œ ์ „์ž์—์„œ CGG ์—ผ๊ธฐ์„œ์—ด๋ฐ˜๋ณต์˜ ํ™•์žฅ์ด ์›์ธ์ด ๋˜๋ฉฐ[26] ๋ˆˆ์ธ๋‘์›์œ„๊ทผ์œก๋ณ‘์€ ์ตœ๊ทผ LRP12, NOTCH2NLC, GIPC1 ๋“ฑ์ด ์›์ธ์œ ์ „์ž๋กœ ๋ณด๊ณ ๋˜๊ณ  ์žˆ๋‹ค[27]. ํŠน์ง•์ ์ธ ์ž„์ƒ์–‘์ƒ๊ณผ ๋”๋ถˆ์–ด ํ…Œ๋‘๋ฆฌ๊ณตํฌ๋ฅผ ๊ด€์ฐฐํ•œ๋‹ค๋ฉด ์ด๋“ค ์งˆํ™˜์„ ์˜์‹ฌํ•  ์ˆ˜ ์žˆ๋‹ค.

4) ์„ธํฌ๋‚ด ๋‹น์›์ถ•์  ๋ฐ ์ง€๋ฐฉ์ถ•์ 

4) ์„ธํฌ๋‚ด ๋‹น์›์ถ•์  ๋ฐ ์ง€๋ฐฉ์ถ•์ 

๊ณจ๊ฒฉ๊ทผ์˜ ์—๋„ˆ์ง€ ๋Œ€์‚ฌ์— ๊ฐ€์žฅ ์ค‘์š”ํ•œ ๊ฒƒ์€ ๋‹น์›๋ถ„ํ•ด์™€ ์ง€๋ฐฉ๋ถ„ํ•ด์ด๋‹ค. ๋”ฐ๋ผ์„œ, ์ด๋“ค ๋Œ€์‚ฌ๊ณผ์ •์—์„œ ์ˆ˜๋ฐ˜๋˜๋Š” ํšจ์†Œ๊ฐ€ ๊ฒฐํ•๋˜๋Š” ๊ฒฝ์šฐ ๋Œ€์‚ฌ๊ทผ์œก๋ณ‘(metabolic myopathy)์ด ๋ฐœ์ƒํ•˜๊ฒŒ ๋œ๋‹ค.
๋จผ์ € ๋‹น์›๋ถ„ํ•ด์™€ ๊ด€๋ จํ•˜์—ฌ ๊ทผ์œก๋ณ‘์„ ์œ ๋ฐœํ•˜๋Š” ํšจ์†Œ๋Š” ๋งค์šฐ ๋‹ค์–‘ํ•œ๋ฐ, ์ด ์ค‘ ์šฉํ•ด์†Œ์ฒดํšจ์†Œ(lysosomal enzyme)์ธ ์‚ฐ์„ฑ์•ŒํŒŒํฌ๋„๋‹นํ™”๋ฌผ๋ถ„ํ•ดํšจ์†Œ(acid-alpha-glucosidase)๊ฐ€ ๊ฐ€์žฅ ๋Œ€ํ‘œ์ ์ด๋ฉฐ ํผํŽ˜๋ณ‘(Pompe disease)์˜ ์›์ธ์ด ๋œ๋‹ค. ํผํŽ˜๋ณ‘์€ ๋ฐœ๋ณ‘ ์—ฐ๋ น์— ๋”ฐ๋ผ ์˜์•„ํ˜•(infantile form)๊ณผ ๊ฒฝ๋„ ์ž„์ƒํ˜•(mild form)์œผ๋กœ ๋‚˜๋ˆ„๋Š”๋ฐ, ์˜์•„ํ˜•์€ ์ถœ์ƒ์‹œ ๊ทผ๊ธด์žฅ์ €ํ•˜, ๊ทผ๋ ฅ์ €ํ•˜ ๋ฐ ์‹ฌ์žฅ๋น„๋Œ€์™€ ๊ฐ„๋น„๋Œ€๋ฅผ ๋™๋ฐ˜ํ•˜๋ฉฐ, ์†Œ์•„์™€ ์„ฑ์ธ์—์„œ ๋ฐœ๋ณ‘ํ•˜๋Š” ๊ฒฝ๋„ ์ž„์ƒํ˜•์˜ ๊ฒฝ์šฐ ์‚ฌ์ง€์˜ ๊ทผ๋ ฅ ์ €ํ•˜์™€ ํ•จ๊ป˜ ํ˜ธํก๊ทผ์˜ ์•ฝํ™”๊ฐ€ ๋™๋ฐ˜๋˜๋Š” ๊ฒƒ์ด ํŠน์ง•์ด๋‹ค. ์กฐ์ง ์†Œ๊ฒฌ์œผ๋กœ ํ—ค๋งˆํ†ก์‹ค๋ฆฐ-์—์˜ค์‹ ์—ผ์ƒ‰์—์„œ ๋‹ค์ˆ˜์˜ ๊ณตํฌ๊ฐ€ ๊ด€์ฐฐ๋˜๋ฉฐ(Fig. 8-A), ์‚ฐ์„ฑ์ธ์‚ฐ์—ผ๋ถ„ํ•ดํšจ์†Œ(acid phosphatase)์—ผ์ƒ‰์—์„œ ๋†’์€ ํ™œ์„ฑ๋„๋ฅผ ๋ณด์ด๊ณ , PAS์—ผ์ƒ‰์—์„œ ๋งค์šฐ ์ง™๊ฒŒ ์—ผ์ƒ‰๋˜๋Š” ๋‹น์›์นจ์ฐฉ(glycogen deposition)์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 8-B) [28]. ํ•˜์ง€๋งŒ ๊ฒฝ๋„ ์ž„์ƒํ˜•์—์„œ๋Š” ๊ณตํฌ๊ฐ€ ๋‘๋“œ๋Ÿฌ์ง€๊ฒŒ ๊ด€์ฐฐ๋˜์ง€ ์•Š์„ ์ˆ˜๋„ ์žˆ์œผ๋ฏ€๋กœ ํŒ๋‹จ์— ์œ ์˜ํ•ด์•ผ ํ•œ๋‹ค. ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ, ํผํŽ˜๋ณ‘์€ ํšจ์†Œ๋Œ€์ฒด์š”๋ฒ•์„ ํ†ตํ•ด ์น˜๋ฃŒ๊ฐ€ ๊ฐ€๋Šฅํ•ด์ง„ ์งˆํ™˜์ด๋ฏ€๋กœ ๊ทผ์œก๋ณ‘์˜ ์ง„๋‹จ์—์„œ ํ•ญ์ƒ ์—ผ๋‘์— ๋‘์–ด์•ผ ํ•œ๋‹ค.
์ง€๋ฐฉ๋Œ€์‚ฌ์— ์ˆ˜๋ฐ˜๋˜๋Š” ๋‹ค์–‘ํ•œ ํšจ์†Œ์˜ ๊ฒฐํ•์€ ์ง€์งˆ์ถ•์ ๋ณ‘(lipid storage disease)์„ ์•ผ๊ธฐํ•˜๋Š”๋ฐ ์กฐ์ง ์†Œ๊ฒฌ์—์„œ ๋‹ค์ˆ˜์˜ ๊ณตํฌ๊ฐ€ ๊ด€์ฐฐ๋˜๋ฉฐ(Fig. 8-C, arrows) oil red O์—ผ์ƒ‰์—์„œ ๊ณตํฌ์— ์ถ•์ ๋œ ์ง€์งˆ์„ฑ๋ถ„์„ ํ™•์ธํ•  ์ˆ˜ ์žˆ๋‹ค(Fig. 8-D) [18]. ์นด๋‹ˆํ‹ด๊ฒฐํ•๋ณ‘(carnitine deficiency)๊ณผ PNPLA2 ์œ ์ „์ž ๋Œ์—ฐ๋ณ€์ด์— ์˜ํ•ด ์ง€๋ฐฉํŠธ๋ผ์ด๊ธ€๋ฆฌ์„ธ๋ผ์ด๋“œ์ง€๋ฐฉ ๋ถ„ํ•ดํšจ์†Œ(adipose triglyceride lipase, ATGL) ๊ฒฐํ•์ด ์ดˆ๋ž˜๋˜์–ด ๋ฐœ์ƒํ•˜๋Š” ์ค‘์„ฑ์ง€์งˆ์ถ•์ ๋ณ‘(neutral lipid storage disease)์ด ์ด๋Ÿฌํ•œ ์กฐ์ง ์†Œ๊ฒฌ์„ ๋ณผ ์ˆ˜ ์žˆ๋Š” ๋Œ€ํ‘œ์ ์ธ ์งˆํ™˜์ด๋‹ค.
๊ณ  ์ฐฐ
๊ณ  ์ฐฐ
๊ทผ์œก์€ ํ•ด๋ถ€ํ•™์  ์ ‘๊ทผ์ด ์šฉ์ดํ•˜์—ฌ ์ƒ๊ฒ€์ด ์–ด๋ ต์ง€ ์•Š์œผ๋ฉฐ ์ƒ๊ฒ€ ํ›„์—๋„ ๊ธฐ๋Šฅ์ ์ธ ๊ฒฐํ•จ์„ ๋‚จ๊ธฐ์ง€ ์•Š์œผ๋ฏ€๋กœ ๊ทผ์œก๋ณ‘์˜ ์ง„๋‹จ์„ ์œ„ํ•ด ๊ทผ์ƒ๊ฒ€์„ ๋น„๊ต์  ์‰ฝ๊ฒŒ ๊ฒฐ์ •ํ•  ์ˆ˜ ์žˆ๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ์นจ์Šต์ ์ธ ์ฒ˜์น˜๋ฅผ ํ•„์š”๋กœ ํ•˜๋ฉฐ ์ง„๋‹จ๊ณผ์ •์ด ๋ถˆ์ถฉ๋ถ„ํ•œ ๊ฒฝ์šฐ ๊ทผ์ƒ๊ฒ€์„ ํ•˜๋”๋ผ๋„ ์œ ์šฉํ•œ ์ •๋ณด๋ฅผ ์–ป์ง€ ๋ชปํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ์œผ๋ฏ€๋กœ ๊ทผ์ƒ๊ฒ€์„ ๊ฒฐ์ •ํ•˜๊ธฐ์— ์•ž์„œ ์‹ ์ค‘ํ•ด์•ผ ํ•œ๋‹ค. ์‚ดํŽด๋ณธ ๋ฐ”์™€ ๊ฐ™์ด ๊ทผ์ƒ๊ฒ€์„ ํ†ตํ•ด ์–ป์„ ์ˆ˜ ์žˆ๋Š” ์กฐ์ง ์†Œ๊ฒฌ๊ณผ ๊ทธ์— ๋”ฐ๋ฅธ ์ •๋ณด๋Š” ๋งค์šฐ ๊ด‘๋ฒ”์œ„ํ•˜๋ฏ€๋กœ ์ •์ƒ์ ์ธ ๊ทผ์œก์กฐ์ง๊ณผ ๋ณ‘์ ์ธ ์ƒํ™ฉ์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์กฐ์ง ์†Œ๊ฒฌ์— ๋Œ€ํ•œ ๊นŠ์€ ์ดํ•ด๊ฐ€ ํ•„์š”ํ•˜๋‹ค. ๋˜ํ•œ ๋น„์ •์ƒ ์กฐ์ง ์†Œ๊ฒฌ์€ ๋น„ํŠน์ด์ ์ธ ๋ณ€ํ™”์ธ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์œผ๋ฏ€๋กœ ๊ฐ๊ฐ์˜ ๋ณ‘๋ฆฌ ์†Œ๊ฒฌ์ด ๊ฐ€์ง€๋Š” ์˜๋ฏธ๋ฅผ ํ•ด์„ํ•˜๋Š” ๋ฐ ์žˆ์–ด ์ฃผ์–ด์ง„ ๋ณ‘๋ ฅ๊ณผ ์‹ ์ฒด์ง„์ฐฐ์„ ํ†ตํ•ด ์–ป์€ ์ž„์ƒ์ •๋ณด๋ฅผ ์ž˜ ํ™œ์šฉํ•ด์•ผ ํ•œ๋‹ค.
๋‹ค์–‘ํ•œ ๊ทผ์œก์งˆํ™˜์„ ์ง„๋‹จํ•˜๋Š” ๋ฐ ์žˆ์–ด ๊ทผ์ƒ๊ฒ€์ด ๊ฐ€์ง€๋Š” ๊ณ ์œ ์˜ ์—ญํ• ์€ ๋ฐ˜๋“œ์‹œ ์กด์žฌํ•˜๋ฏ€๋กœ ์ด๋ฅผ ๊ฐ„๊ณผํ•˜์ง€ ์•Š์•„์•ผ ํ•˜๋ฉฐ ํ•œํŽธ ๊ทธ ์—ญํ• ์ด ๊ณผ์žฅ๋˜์–ด์„œ๋„ ์•ˆ ๋œ๋‹ค. ๊ทผ์œก์งˆํ™˜์„ ์ง„๋‹จํ•˜๋Š” ์—ฌ๋Ÿฌ ๊ฐ€์ง€ ๋„๊ตฌ ์ค‘ ํ•˜๋‚˜๋กœ์จ ๊ทผ๋ณ‘๋ฆฌ๋ฅผ ์ž˜ ์ดํ•ดํ•˜๊ณ  ์ด๋Ÿฌํ•œ ์ดํ•ด๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ๊ทผ์ƒ๊ฒ€์„ ์ž˜ ํ™œ์šฉํ•œ๋‹ค๋ฉด ๋‹ค์–‘ํ•œ ๊ทผ์œก์งˆํ™˜์„ ์ง„๋‹จํ•˜๋Š” ๋ฐ ๋งŽ์€ ๋„์›€์ด ๋  ๊ฒƒ์ด๋‹ค.

Figureย 1.
Normal muscle pathology. (A, B) Normal muscle fibers are polygonal shaped and have multiple nuclei in the periphery (A: hematoxylin and eosin stain, ร—200; B: modified Gomori-Trichrome stain, ร—200). (C) Darkly stained fibers are type 1 fibers while type 2 fibers are lightly stained in pH 4.3 of adenosine triphosphatase (ATPase) stain (ATPase, pH 4.3, ร—200). (D) At pH 9.4 of ATPase stain, fibers are inversely stained; type 1 fibers are light, and type 2 are dark (ATPase, pH 9.4, ร—200).
jkna-39-4-274f1.tif
Figureย 2.
Changes in fiber size and types. (A) In muscular dystrophies, atrophic and hypertrophic fibers are randomly mixed. Muscle fibers are round-shaped and interstitial connective tissues are markedly increased (hematoxylin and eosin [H&E], ร—100). (B) Most of muscle fibers are small-sized and round-shaped in congenital myopathies (H&E, ร—100). (C) At pH 4.3 of adenosine triphosphatase (ATPase) stain, darkly stained type 1 fibers are small-sized and predominant in number (congenital fiber type disproportion, ร—100). (D) Muscle fibers in the periphery of fascicles are relatively smaller than the others, which is defined as perifascicular atrophy (nicotinamide dehydrogenase-tetrazolium reductase stain, ร—100). (E) Atrophic fibers are angular shaped, and the same type of fibers are grouped (fiber type grouping) (ATPase, pH 4.3, ร—100). (F) Small-sized fibers are clustered forming a group, which is called as โ€˜grouped atrophyโ€™ (H&E, ร—100).
jkna-39-4-274f2.tif
Figureย 3.
Muscle fiber necrosis and regeneration. (A) In necrotic fibers sarcoplasm is faintly stained (arrows), which is why they are called as โ€˜hyalineโ€™ or โ€˜liquefiedโ€™ fibers (hematoxylin and eosin [H&E], ร—200). (B) A necrotic fiber is phagocytosed by macrophages (arrowhead), and regenerating fibers have basophilic sarcoplasm with enlarged nuclei (arrows) (H&E, ร—200) (C) Activities of acid phosphatase appear highly elevated in immune-mediated necrotizing myopathy (acid phosphatase, ร—100).
jkna-39-4-274f3.tif
Figureย 4.
Inflammatory infiltration. (A) Inflammatory cells are infiltrated in perimysium and around vessels (dermatomyositis, hematoxylin and eosin [H&E], ร—100). (B) Inflammatory infiltration is highlighted in endomysial spaces (polymyositis, H&E, ร—200). (C) Inflammatory cells are surrounding non-necrotic fibers (arrows) (inclusion body myositis, H&E, ร—100).
jkna-39-4-274f4.tif
Figureย 5.
Nuclear changes and related findings. (A) Many of muscle fibers have nuclei internally (centronuclear myopathy, hematoxylin and eosin [H&E], ร—100). (B) Severely atrophied fibers have clustered nuclei with minimal sarcoplasm, which is called as โ€˜nuclear clumpsโ€™ (arrows) (H&E, ร—200). (C) In a longitudinal section, nuclei are serially arranged forming a chain (H&E, ร—200). (D) Almost all fibers have a single nucleus in the center of muscle fibers. Centronuclear myopathy (H&E, ร—200). (E) Sarcoplasmic strands are radially arranged from the center where the nucleus is located (centronuclear myopathy, nicotinamide dehydrogenase tetrazolium-reductase [NADH-TR], ร—200). (F) The peripheries of muscle fibers are faintly stained in NADH-TR stain, which is called as โ€˜peripheral haloโ€™ (myotubular myopathy, NADH-TR, ร—400).
jkna-39-4-274f5.tif
Figureย 6.
Mitochondrial changes and related findings. (A) Ragged red fibers have red-colored sarcoplasm because abnormal mitochondria are highlighted in modified Gomori-Trichrome (mGT) stain (chronic progressive external ophthalmoplegia [CPEO], mGT, ร—200). (B) More bluish colored fibers are ragged-blue fibers, which are corresponding to ragged red fibers (CPEO, succinate dehydrogenase stain, ร—200). (C) Many fibers indicated by asterisks are deficient for cytochrome c oxidase (COX) stain (CPEO, COX, ร—200). (D) The peripheries of fibers are darkly stained in lobulated fibers (chronic myopathy, nicotinamide dehydrogenase tetrazolium-reductase stain, ร—200).
jkna-39-4-274f6.tif
Figureย 7.
Myofibrillar changes and abnormal inclusions. (A) Round-shaped zones in the center of fibers are deficient for nicotinamide dehydrogenase tetrazolium-reductase (NADH-TR) stain, which is called as โ€˜central coreโ€™ (central core disease, NADH-TR, ร—200). (B) A core indicated by an arrow is surrounded by darkly stained intermediate zone. This fiber is called as โ€˜target fiberโ€™ (neurogenic change, NADH-TR, ร—200). (C) In several muscle fibers, sarcoplasm is partially defective, which is called as โ€˜moth-eaten appearanceโ€™ (arrows; inflammatory myopathy, NADH-TR, ร—200). (D) Nemaline bodies are appeared as red-colored, dot-like shape, and scattered in sarcoplasm (nemaline myopathy, modified Gomori-Trichrome [mGT], ร—200). (E) Compact, red-colored inclusions (cytoplasmic bodies) are distributed in a muscle fiber (arrows) (myofibrillar myopathy, mGT, ร—200). (F) Green-colored, amorphous inclusions (spheroid bodies) are shown (arrow; myofibrillar myopathy, mGT, ร—200). (G) Vacuoles with red-colored rims (rimmed vacuoles) are present in scattered fibers (GNE myopathy, mGT, ร—200).
jkna-39-4-274f7.tif
Figureย 8.
Metabolic myopathies. (A) Many fibers have vacuoles inside, which are positive for PAS (B) (pompe disease; A: hematoxylin and eosin [H&E], ร—200; B: PAS, ร—200). (C) Multiple tiny droplets are observed in scattered fibers (arrows) (neutral lipid storage disease, H&E, ร—200). (D) Lipid accumulation is highlighted in oil red O stain (neutral lipid storage disease, oil red O, ร—100).
jkna-39-4-274f8.tif
REFERENCES
REFERENCES

1. Dubowitz V, Sewry CA. The procedure of muscle biopsy. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;2-15.

2. Kim DS. Diagnostic significance of immunohistochemical staining in muscular dystrophy. J Korean Neurol Assoc 2006;24:1-13.

3. Dubowitz V, Sewry CA. Normal muscle. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;28-54.

4. Sewry CA, Goebel HH. General pathology of muscle disease. In: Goebel HH, Sewry CA, Weller RO, eds. Muscle disease: pathology and genetics. 2nd ed. Oxford: Wiley-Blackwell, 2013;19-31.

5. Dubowitz V, Sewry CA. Muscular dystrophies and allied disorders I: Duchenne and Becker muscular dystrophy. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;250-275.

6. Park YE, Shin JH, Kim HS, Lee CH, Kim DS. Characterization of congenital myopathies at a Korean neuromuscular center. Muscle Nerve 2018;58:235-244.
[Article] [PubMed]
7. Dubowitz V, Sewry CA. Inflammatory myopathies. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;513-538.

8. Barresi R, Brown SC. Dystrophin and its associated glycoprotein complex. In: Goebel HH, Sewry CA, Weller RO, eds. Muscle disease: pathology and genetics. 2nd ed. Oxford: Wiley-Blackwell, 2013;95-101.

9. Dubowitz V, Sewry CA. Muscular dystrophies and allied disorders II: Limb-girdle muscular dystrophies. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;276-301.

10. Dubowitz V, Sewry CA. Muscular dystrophies and allied disorders IV: Emery-Dreifuss muscular dystrophy and similar syndromes. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;331-344.

11. Dubowitz V, Sewry CA. Muscular dystrophies and allied disorders III: Congenial muscular dystrophies and associated disorders. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;302-330.

12. Tanboon J, Nishino I. Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol 2019;32:704-714.
[Article] [PubMed]
13. Hauerslev S, ร˜rngreen MC, Hertz JM, Vissing J, Krag TO. Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy. Acta Neurol Scand 2013;128:194-201.
[Article] [PubMed]
14. Mariano A, Henning A, Han R. Dysferlin-deficient muscular dystrophy and innate immune activation. FEBS J 2013;280:4165-76.
[Article] [PubMed]
15. Park YE, Choi YC, Bae JS, Lee CH, Kim HS, Shin JH, et al. Clinical and pathological features of Korean patients with DNM2-related centronuclear myopathy. J Clin Neurol 2014;10:24-31.
[Article] [PubMed] [PMC]
16. Romero NB, Laforte J. Centronuclear myopathies. In: Goebel HH, Sewry CA, Weller RO, eds. Muscle disease: pathology and genetics. 2nd ed. Oxford: Wiley-Blackwell, 2013;134-144.

17. Sewry CA, Quinlivan RC, Squier W, Morris GE, Holt I. A rapid immunohistochemical test to distinguish congenital myotonic dystrophy from X-linked myotubular myopathy. Neuromuscul Disord 2012;22:225-230.
[Article] [PubMed]
18. Dubowitz V, Sewry CA. Metabolic myopathies II: lipid-related disorders and mitochondrial myopathies. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;446-484.

19. Seok JI, Kim DS, Park MS, Nam TS, Song HS, Park YE, et al. Clinical and pathological features of clevudine induced myopathy. J Korean Neurol Assoc 2013;31:26-31.

20. Jungbluth H. Core myopathies, malignant hyperthermia susceptibility and Brody disease. In: Goebel HH, Sewry CA, Weller RO, eds. Muscle disease: pathology and genetics. 2nd ed. Oxford: Wiley-Blackwell, 2013;214-224.

21. Lee JM, Lim JG, Shin JH, Park YE, Kim DS. Clinical and genetic diversity of nemaline myopathy from a single neuromuscular center in Korea. J Neurol Sci 2017;383:61-68.
[Article] [PubMed]
22. Uruha A, Benveniste O. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Curr Opin Neurol 2017;30:457-463.
[Article] [PubMed]
23. Park YE, Shin JH, Kang B, Lee CH, Kim DS. NEB-related core-rod myopathy with distinct clinical and pathological features. Muscle Nerve 2016;53:479-484.
[Article] [PubMed]
24. Selcen D. Myofibrillar myopathies. Neuromuscul Disord 2011;21:161-171.
[Article] [PubMed] [PMC]
25. Park YE, Kim DS, Choi YC, Shin JH. Progression of GNE myopathy based on the patient-reported outcome. J Clin Neurol 2019;15:275-284.
[Article] [PubMed] [PMC]
26. Malerba A, Klein P, Bachtarzi H, Jarmin SA, Cordova G, Ferry A, et al. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 2017;8:14848.
[Article] [PubMed] [PMC]
27. Ishiura H, Shibata S, Yoshimura J, Suzuki Y, Qu W, Doi K, et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat Genet 2019;51:1222-1232.
[Article] [PubMed]
28. Dubowitz V, Sewry CA. Metabolic myopathies I: glycogenosis and lysosomal myopathies. In: Dubowitz V, Sewry CA, Oldfors A, Lane R, eds. Muscle biopsy: a practical approach. 4th ed. London: Elsevier, 2013;423-435.

Go to Top